MODVQ DEF 14A DEF-14A Report April 26, 2024

MODIVCARE INC

10-Ks and 10-Qs

10-Q	Quarter ended March 31, 2025
10-K	Fiscal year ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-Q	Quarter ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-K	Fiscal year ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-Q	Quarter ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-K	Fiscal year ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-Q	Quarter ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-K	Fiscal year ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-Q	Quarter ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-K	Fiscal year ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-Q	Quarter ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-K	Fiscal year ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-Q	Quarter ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-K	Fiscal year ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-Q	Quarter ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-K	Fiscal year ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-Q	Quarter ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-K	Fiscal year ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-Q	Quarter ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-K	Fiscal year ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-Q	Quarter ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-K	Fiscal year ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-Q	Quarter ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-K	Fiscal year ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-Q	Quarter ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-K	Fiscal year ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-K	Fiscal year ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-Q	Quarter ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-K	Fiscal year ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-Q	Quarter ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-K	Fiscal year ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on April 30, 2025
DEF 14A	Filed on March 3, 2025
DEF 14A	Filed on Feb. 3, 2025
DEF 14A	Filed on April 29, 2024
DEF 14A	Filed on April 26, 2024
DEF 14A	Filed on May 1, 2023
DEF 14A	Filed on June 14, 2022
DEF 14A	Filed on May 2, 2022
DEF 14A	Filed on April 30, 2021
DEF 14A	Filed on April 29, 2020
DEF 14A	Filed on April 26, 2019
DEF 14A	Filed on April 27, 2018
DEF 14A	Filed on April 28, 2017
DEF 14A	Filed on June 14, 2016
DEF 14A	Filed on July 29, 2015
DEF 14A	Filed on June 16, 2014
DEF 14A	Filed on April 26, 2013
DEF 14A	Filed on July 16, 2012
DEF 14A	Filed on April 20, 2011
DEF 14A	Filed on April 22, 2010

modv-20240426

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

Information Required in Proxy Statement

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrant ☒

Filed by a Party other than the Registrant ☐

Check the appropriate box:


☐			Preliminary Proxy Statement
☐			Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☒			Definitive Proxy Statement
☐			Definitive Additional Materials
☐			Soliciting Material Pursuant to §240.14a-12

ModivCare Inc.

(Name of Registrant as Specified In Its Charter)

Not Applicable

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):


☒			No fee required.
☐			Fee paid previously with preliminary materials.
☐			Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a‑6(i)(1) and 0‑11.

Dear Stockholder:

April 26, 2024

We are pleased to invite you to attend the 2024 Annual Meeting of Stockholders of ModivCare Inc., which will be held on Tuesday, June 11, 2024, at 10:00 a.m. Mountain Daylight Time, at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237.

At the annual meeting you will be asked to consider and vote on the proposals described in the accompanying notice of annual meeting and proxy statement, as well as such other business as may properly come before the annual meeting.

Your vote is important, and we encourage you to vote promptly. For record holders, regardless of whether you are able to attend the upcoming annual meeting in person, please follow the instructions contained in the proxy statement on how to vote via the Internet, by telephone, or request a paper proxy card to complete, sign and return by mail so that your shares may be voted. If your shares are held in the name of a broker, bank or other intermediary holder of record, follow the voting instructions you receive from the holder of record to vote your shares.

On behalf of the board of directors and management of the Company, I extend our appreciation for your continued support.

L. Heath Sampson

President, Chief Executive Officer and Director

Notice of
Annual Meeting
of Stockholders

To our Stockholders:

Notice is hereby given that the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of ModivCare Inc., a Delaware corporation (the “Company”), will be held at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237, at 10:00 a.m. Mountain Daylight Time on Tuesday, June 11, 2024. The Annual Meeting is being held for the following purposes:

Meeting

Date

____

June 11, 2024

To elect six directors to serve for one-year terms;

To hold a non-binding advisory vote to approve named executive officer compensation;

Meeting

Time

____

10:00 a.m.

Mountain Daylight Time

To ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the 2024 fiscal year; and

To transact such other business as may properly come before the Annual Meeting or any adjournment, postponement or rescheduling thereof.

Meeting

Place

____

6900 E. Layton Avenue, 12th Floor

Denver, CO 80237

Only stockholders of record of the Company’s common stock, $0.001 par value per share, as shown by the transfer books of the Company, at the close of business on April 16, 2024, are entitled to notice of, and to vote at, the Annual Meeting or any adjournment, postponement or rescheduling thereof.

All stockholders are cordially invited to attend the Annual Meeting in person. To ensure your representation at the Annual Meeting, however, you are urged to vote your shares in advance of the Annual Meeting by using one of the methods outlined in the proxy statement.

By Order of the Board of Directors,

Jennifer Jaskolka

Vice President & Deputy General Counsel



			Your vote is important. ____ In order to ensure your representation at the meeting, please vote your shares using one of the methods outlined in the accompanying proxy statement as promptly as possible. See “Voting Procedures” in the proxy statement for further details. If you do attend the meeting, you may, if you prefer, revoke your proxy and vote your shares in person.

Important Notice Regarding the Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on Tuesday, June 11, 2024. The Proxy Statement, form of proxy card and our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 are available free of charge at www.proxyvote.com.

We have elected to provide access to you to our proxy materials over the Internet, and we have mailed to you a Notice of Internet Availability of Proxy Materials with instructions for accessing our proxy materials and voting via the Internet and for how you may obtain paper copies of our proxy materials if you so choose.

Table of Contents


1			Proxy Statement for 2024 Annual Meeting of Stockholders
2			Proxy Statement Summary
5			Voting Procedures
8			Voting Securities of Certain Beneficial Owners and Management
10			Proposal 1 Election of Directors
20			Corporate Governance
30			Executive Compensation
56			Proposal 2 Advisory vote to approve named executive officer compensation
58			Proposal 3 Ratification of appointment of independent registered public accounting firm
59			Audit Committee Report
60			Independent Registered Public Accountants
61			Stockholder Proposals for 2025 Annual Meeting
62			Other Matters
63			Additional Information
64			Householding

Proxy Statement For 2024
Annual Meeting of Stockholders

2024 Annual Meeting of Stockholders

This proxy statement (the “Proxy Statement”) is furnished in connection with the solicitation of proxies by the Board of Directors (the “Board”) of ModivCare Inc., a Delaware corporation (the “Company”), for use at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company, to be held at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237, at 10:00 a.m. Mountain Daylight Time on Tuesday, June 11, 2024, and at any adjournment, postponement or rescheduling of the meeting, for the purposes set forth herein and in the attached notice of the Annual Meeting.

As is the practice of many other companies, the Company provides proxy materials by a “notice and access” process through the Internet. Those stockholders who wish to receive paper proxy materials may request a complimentary copy from the Company by following the instructions on the notice they received.

Only stockholders of record, as shown on the transfer books of the Company, at the close of business on April 16, 2024 (the “Record Date”) will be entitled to notice of, and to vote at, the Annual Meeting or any adjournment, postponement or rescheduling thereof. On the Record Date, there were 14,194,934 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), outstanding and entitled to vote at the Annual Meeting, excluding 15,948 restricted shares of Common Stock that do not have the right to vote. The Common Stock is the only outstanding class of capital stock of the Company with voting rights. The Common Stock votes as a single class, with each share of Common Stock entitled to one vote on each matter to be considered at the Annual Meeting.

The principal executive offices of the Company are located at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237 and the telephone number of the Company is (800) 486-7647. To obtain directions to the location of our principal executive offices, where the Annual Meeting will be held in person, please contact our Corporate Secretary at that address or telephone number. References to the “Company,” “ModivCare,” “we,” “us” or “our” and similar terms mean ModivCare Inc. and, except as otherwise specified herein, its subsidiaries. When such terms are used in reference to the Common Stock, they refer specifically to ModivCare Inc.

This Proxy Statement and accompanying proxy card are being provided to Company stockholders on or about April 26, 2024.


Modivcare 2024 Proxy Statement			1


			TABLE OF CONTENTS

Proxy Statement Summary

Corporate Governance Highlights

We have structured our corporate governance program to promote the long-term interests of stockholders, strengthen the accountability of our Board and management, and help build public trust in the Company.

Highlights of our efforts include:

Proposals to Be Voted Upon at the Annual Meeting

Proposal Description

Board Recommendation

Where to Find More Information

Separation of the Chair of the Board and Chief Executive Officer roles

Election of six Directors

FOR

all nominees

All Board committees chaired by independent directors, and all directors are independent other than our CEO director

Approval of non-binding advisory vote to approve named executive officer compensation

FOR

Active Board and Board committee role in overseeing management of the Company’s risks

Ratification of appointment of KPMG LLP as the independent registered public accounting firm of the Company for 2024

FOR

Annual Board and Board committee self-evaluations

Equity ownership guidelines for directors and executive officers

About the Company

ModivCare Inc. is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for public and private payors and their members. Its value-based solutions address the social determinants of health, or SDoH, by connecting members to essential care services. By doing so, ModivCare helps health plans manage risks, reduce costs, and improve health outcomes. ModivCare is a provider of non-emergency medical transportation, or NEMT, personal care services, or PCS, and remote patient monitoring solutions, or RPM, which serve similar, highly vulnerable patient populations. The technology-enabled operating model in its NEMT segment includes the coordination of non-emergency medical transportation services supported by an infrastructure of core competencies in risk underwriting, contact center management, network credentialing, and claims management. Additionally, services provided in its PCS segment include placements of non-medical personal care assistants, home health aides and nurses primarily to Medicaid patient populations in need of care monitoring and assistance performing daily living activities in the home setting. ModivCare’s remote patient monitoring solutions in its RPM segment include the monitoring of personal emergency response systems, or PERS, vitals monitoring, medication management and data-driven patient engagement solutions.

Cash and equity award plans with clawback provisions

Anti-hedging and anti-pledging policies for directors and executive officers

Reasonable director tenure, with an average of seven years of service

Regular executive sessions of non-employee directors

No poison pill


2			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Proxy Statement Summary

Business Highlights

During 2023, the Company continued the evolution of its business and technology that had positive impacts on our clients, transportation providers and members. We also enhanced our executive leadership, resulting in an experienced team with a track record of operational excellence, including the addition of veteran leaders with the addition of Anne Bailey, President of ModivCare Home, Barbara Gutierrez, Chief Financial Officer, Henry Toledo, Chief People Officer, and Jessica Kral, Chief Information Officer. We made progress building for scale through our integration efforts in 2023 which included general ledger and personnel management system integrations and made continued investment in our data analytics capabilities, which we expect to continue in 2024. The Company maintained its membership at approximately 34 million monthly members in our Mobility segment despite Medicaid redetermination headwinds and we grew our Personal Care caregiver base. We integrated digital workforce resources, including onboarding, training, and scheduling for caregivers and expanded our virtual processes in 2023 which contributed to an increase in our caregiver satisfaction score, resulting in an increase in the number of caregivers.

Performance Highlights

The efforts of this talented leadership team during 2023 resulted in the Company continuing to produce solid financial results despite the challenging and uncertain macroeconomic environment. This strong financial performance is evidenced by the Company reporting substantial revenue growth in the last three years as compared to the two years prior, as well as sustained growth in Adjusted EBITDA* with a CAGR of 38% over the last five years, as illustrated below.

1. The increase in revenue from 2020 to 2021 is related to the acquisition of Simplura Health Group in November 2020. The increase in revenue from 2021 to 2022 is related to the acquisitions of Care Finders Total Care, LLC and VRI Intermediate Holdings, LLC, both in September 2021.

2. The net loss in 2023 is related to a goodwill impairment charge that was recorded during the second quarter of 2023.

3. Adjusted EBITDA is a financial measure that is not presented in accordance with accounting principles generally accepted in the United States of America, or GAAP. A reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable GAAP financial measure, is provided in Appendix A to this Proxy Statement. The increase in Adjusted EBITDA from 2019 to 2020 is related to lower operating expenses as a result of the COVID-19 pandemic and related mandated stay at home order, which reduced utilization of non-emergency healthcare services.

Executive Compensation Highlights

ModivCare’s executive compensation philosophy is designed to attract, motivate and retain highly talented individuals by:

Designing aggregate total direct compensation to be competitive while allowing Company and/or individual performance to drive actual compensation up or down

Ensuring that there is a strong link between pay and performance against our business strategy, the metrics in our incentive programs, and the business results driving stockholder value

Aligning performance-driven compensation with stockholder interests, with a percentage of total pay tied to stock performance

Mitigating financial risk through sound plan design and decision-making, and with ongoing oversight

Our Compensation Committee uses balanced compensation practices to ensure that there is alignment in pay for performance for our executives.


Modivcare 2024 Proxy Statement			3


Proxy Statement Summary			TABLE OF CONTENTS

Diversity, Equity and Inclusion Highlights

Our team members reflect the communities in which they live and work as well as the members they serve. This provides them with the background and broad range of experiences that have helped us achieve our success to date. A key component of our growth and success is our focus on diversity, equity and inclusion as well as a sense of belonging. We believe this commitment allows us to better understand member needs, while developing processes and solutions to meet those needs. We have made progress in our workforce diversity representation, including having a majority of our team members who identify as an underrepresented minority. We continue to work on improving this important area. We have established goals to continue advancing our hiring, development, and retention of diverse team members and our overall diversity representation, including within our executive leadership team as this effort aligns with being a socially responsible community member. Impacts of the Company’s diversity, equity, inclusion and belonging initiatives include:

• A 9-member Board that includes one member who identifies as a female and two members who identify as an underrepresented minority.

• Company-wide leadership ranks (director and above) that consist of approximately 37% of individuals who identify as an underrepresented minority and approximately 48% who identify as female.

• Further enhancement of the diversity of our executive team with the addition of Anne Bailey, President of ModivCare Home, Jessica Kral, Chief Information Officer, and Barbara Gutierrez, Chief Financial Officer, who identify as female, and Henry Toledo, Chief People Officer, who identifies as an underrepresented minority.

• Formation of seven Employee Resource Groups (“ERGs”), which are team member-led, experience-based groups of individuals that share a common interest in diversity topics including, but not limited to, race, ethnicity, national origin, veteran status, gender, and sexual orientation/gender identity. Our seven ERGs include focus on Ability Awareness, Black and African Affinity, Women’s Empowerment Network (“W.E.N.”), Pride, Fostering Inclusivity, Engagement, Support Through Action (“F.I.E.S.T.A.”), One Asian American and Pacific Islanders (“OneAAPI”), and Veterans. During 2023, the Company created a Diversity, Equity, and Inclusion Council ("DEI Council"), which included co-chairs and executive sponsors from each ERG. The DEI Council’s purpose is to facilitate collaboration among the ERGs and to continue the advancement of the Company’s DEI initiatives.

Environmental, Social and Governance Highlights

We are committed to furthering our Environmental, Social and Governance (“ESG”) and sustainability practices which are intended to create value for our stockholders and other stakeholders by building trust, driving innovation, mitigating risk, fostering team member engagement, increasing productivity and reducing costs. As a mission-driven supportive care services company, we are committed to integrating sustainability into our business strategy while addressing the social determinants of health. We are committed to responsible corporate citizenship and we continue to make progress on our sustainability initiatives as we provide high quality care and services every day to approximately 34 million members nationwide. While we are in the early stages of this journey, we are committed to advancing our sustainability practices as we focus on leveling the inequities in healthcare through our supportive care services, whether by providing a ride to a healthcare appointment, assisting with activities of daily living or engaging with a member who has a health emergency. We believe that these critical services should be provided equitably nationwide, especially for the most vulnerable populations. We focus on sustainability risks and opportunities that are believed to be the most relevant to our business and the most impactful to our stakeholders and the communities we serve. We have a goal that all of our team members strive to advance our sustainability initiatives in their daily routines as we work to drive positive health outcomes by transforming how we connect people to care. We published our 2022 ESG Report in May 2023 to showcase the achievements we have made related to ESG. The ESG report is accessible on ModivCare’s Investor Relations website at investors.modivcare.com. We have aligned the content of this report to our sustainability framework, composed of the following four pillars:

Responsible Business Practices

Member Support

Our Team

Environmental Management

We are committed to upholding ethical business practices, operating with high standards of compliance and corporate governance, and managing the business in a manner consistent with our values and purpose.

We are committed to providing vulnerable populations supportive services in a safe and ethical way, enabling greater access to care, reducing costs, and improving outcomes.

We “Care Big” for our team - our greatest asset - by fostering a diverse, inclusive, and safe workplace where our team members can learn, develop, contribute, thrive, and have a sense of belonging.

We are monitoring the environmental impact from our operational footprint, vendors and partners, in alignment with our intentions of responsible environmental stewardship.


4			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS

Voting Procedures

The presence, in person or represented by proxy, of the holders of a majority of the outstanding shares of Common Stock entitled to vote at the Annual Meeting will constitute a quorum for the transaction of business at the Annual Meeting. Abstentions will be included in the number of shares present at the Annual Meeting for the purposes of determining the presence of a quorum. So-called “broker non-votes” (that is, when a broker or other entity that is the record holder of shares of Common Stock votes on a “routine matter” (as discussed below) without voting instructions from the beneficial owner but cannot vote on another particular proposal because the broker or other entity does not have discretionary voting power with respect to that proposal and has not received voting instructions from the beneficial owner regarding that proposal) are not relevant in determining the absence or presence of a quorum at the Annual Meeting.

If you hold your shares in “street name” (that is, your shares are held in an account at and registered in the name of a brokerage firm, bank, broker-dealer or similar organization), your broker or other organization may exercise discretion to vote your shares under limited circumstances if you do not provide voting instructions before the Annual Meeting. These circumstances include voting your shares on so-called “routine matters,” such as the ratification of the appointment of our independent registered public accounting firm. With respect to routine matters, if you do not vote your shares, your bank, broker or other organization may vote your shares on your behalf or leave your shares unvoted. The election of directors and the non-binding advisory vote approving executive compensation, however, are not considered routine matters. When a proposal is not a routine matter and the brokerage firm or other organization has not received specific voting instructions from the beneficial owner of the shares with respect to that proposal, the brokerage firm cannot vote the shares on that proposal. In circumstances when there are both routine matters and non-routine matters being considered at the same meeting, such as at our upcoming Annual Meeting, the record owner brokers or other organizations that do not receive specific voting instructions from their beneficial owners are “entitled to vote” on the routine matter but not “entitled to vote” on the non-routine matters. This circumstance results in a “broker non-vote” on each of the non-routine matters. Accordingly, it is particularly important that beneficial owners instruct their brokers or other organizations how they wish to vote their shares on all matters to ensure their votes are counted as intended.

Approval of Proposal 1

Requires that the number of votes cast for each director nominee must exceed the number of votes cast against each director nominee. Abstentions and broker non-votes are not considered votes cast for or against the election of directors and thus will have no effect on the election of directors. In accordance with the Company’s Amended and Restated Bylaws (the “Bylaws”), cumulative voting is not permitted for the election of directors.

Approval of Proposal 2

Requires the affirmative vote of the majority of shares present in person or represented by proxy and entitled to vote on the proposal at the Annual Meeting. Abstentions are considered present and entitled to vote on Proposal 2 and will have the same legal effect as votes against such proposal. As a non-routine matter, we expect broker non-votes on this proposal, however, these broker non-votes will not count as votes for or against such proposal at the Annual Meeting because they represent shares not “entitled to vote” on the matters and thus will have no effect on the outcome of the voting on this proposal.

Approval of Proposal 3

Requires the affirmative vote of the majority of shares present in person or represented by proxy and entitled to vote on the proposal at the Annual Meeting. Abstentions are considered present and entitled to vote on Proposal 3 and will have the same legal effect as votes against such proposal. There are not expected to be any broker non-votes associated with this proposal, as the ratification of the appointment of our independent registered public accounting firm is a routine matter upon which record holder brokers and other organizations are entitled to vote the shares without specific instructions from their beneficial owners. As a result, if your shares are held in “street name” and you do not give your bank, broker or other organization instructions on how to vote, your shares may be voted by the bank, broker or other organization in its discretion.

Notice and Access

The Company uses the Internet as the primary means of furnishing proxy materials to stockholders. Stockholders will have received a Notice of Internet Availability of Proxy Materials (the “Notice”) with instructions for accessing the full proxy materials and voting via the Internet. The Notice will also provide information on how stockholders may obtain, without charge, paper copies of our proxy materials. The Company’s proxy materials are also available at www.proxyvote.com.


Modivcare 2024 Proxy Statement			5


Voting Procedures			TABLE OF CONTENTS

Stockholder of Record

If you are the stockholder of record with respect to your shares (that is, your shares are registered directly in your name with the Company’s transfer agent, Computershare Trust Company, N.A.), you may vote using the following methods:


						In Person. You may vote in person at the Annual Meeting by requesting a ballot from a Company representative when you arrive.
						Internet. You may vote by Internet at www.proxyvote.com. You will be prompted to enter your Control Number located on the Notice or proxy card and then follow the instructions provided to vote.
						Telephone. You may vote by telephone at (800) 690-6903. You will be prompted to enter your Control Number located on the Notice or proxy card and then follow the instructions provided to vote.
						Mail. If you requested printed copies of the proxy materials by mail, you may vote by proxy at the Annual Meeting by filling out the proxy card and following the voting instruction form included with your proxy materials and returning the properly completed proxy card in the envelope provided.

The deadline for registered stockholders to vote by Internet, telephone or mail is 11:59 p.m. Eastern Time on June 10, 2024.

Beneficial Owner of Shares Held in Street Name

If you are the beneficial owner of shares held in street name (that is, your shares are held in an account at and registered in the name of a brokerage firm, bank, broker-dealer or similar organization), you may vote using the following methods:


						In Person. You must obtain a “legal proxy” from the organization that holds your shares. A legal proxy is a written document that authorizes you to vote your shares held in street name at the Annual Meeting. Please contact the organization that holds your shares for instructions regarding obtaining a legal proxy. You must bring a copy of the legal proxy to the Annual Meeting and ask for a ballot from a Company representative when you arrive. In order for your vote to be counted, you must hand both the copy of the legal proxy and your completed ballot to a Company representative to be provided to the inspector of elections.
						Internet and Telephone. See the materials you received from your broker or other record holder organization to determine your ability to instruct your broker or other organization how you wish to cast your vote by Internet or telephone.
						Mail. If you requested printed copies of the proxy materials by mail, you may vote by following the instructions of your bank, broker or other organization about how you wish to cast or instruct your organization how to cast your vote.

Changing or Revoking Your Vote

If you are a record holder of shares of Common Stock, after voting, you may change your vote one or more times by completing and returning a later dated and new proxy card to the Company, by voting again either by Internet or telephone as described in this Proxy Statement, or by voting in person at the Annual Meeting. You may request a new proxy card from the Company’s Corporate Secretary at the address below. You may revoke a proxy before its exercise by filing written notice of revocation with the Company’s Corporate Secretary at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237, before the Annual Meeting. The last vote received chronologically will supersede any prior votes. The deadline for registered stockholders to change their vote by Internet or telephone is 11:59 p.m. Eastern Time on June 10, 2024.

If you hold your shares as a beneficial holder through a brokerage firm, bank, broker-dealer or similar organization, please refer to your organization’s proxy card or other information forwarded by such organization to learn how you can revoke your proxy instructions and change your or your organization’s vote.


6			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Voting Procedures

Failure to Provide Voting Instructions

Other than with respect to broker non-votes, if you submit a signed proxy card or vote by Internet or telephone, but do not indicate how you want your shares voted, the persons acting as proxies will vote your shares of Common Stock:

“FOR”

the election of the director nominees, Todd J. Carter, David A. Coulter, Garth Graham, Leslie V. Norwalk, Rahul Samant, and L. Heath Sampson;

“FOR”

the non-binding advisory vote to approve named executive officer compensation;

“FOR”

the ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the 2024 fiscal year.

With respect to any other matter that properly comes before the Annual Meeting, which is not expected, the proxy holders will vote the proxies in their discretion in accordance with their best judgment and in the manner they believe to be in the best interests of the Company and its stockholders.

Solicitation of Proxies

The entire cost of soliciting proxies, including the costs of preparing, assembling and, to the extent applicable, mailing the Notice, this Proxy Statement, the proxy card and any additional soliciting materials furnished to stockholders, will be borne by the Company. In addition to solicitation by mail, officers, directors or employees of the Company may solicit proxies in person or by telephone, facsimile or similar means without additional compensation. Upon request, the Company will pay the reasonable expenses incurred by record holders of the Common Stock who are brokers, dealers, banks or voting trustees, or their nominees, for sending proxy materials and the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report”) to the beneficial owners of the shares they hold of record.

As mentioned above, the Company is not presently aware of any matters that will be brought before the Annual Meeting that are not reflected in the attached Notice of the Annual Meeting. If any such matters are brought before the Annual Meeting, the persons acting as proxies will act or vote in accordance with their best judgment.


Modivcare 2024 Proxy Statement			7


			TABLE OF CONTENTS

Voting Securities of Certain Beneficial Owners and Management

The following table sets forth certain information, as of the Record Date, with respect to the beneficial ownership of ModivCare’s Common Stock by (a) each stockholder known by us to own beneficially more than 5% of the outstanding voting power of our Common Stock, (b) each of ModivCare’s directors and nominees for director, (c) each of ModivCare’s executive officers named in the “Summary Compensation Table” which follows, who are our named executive officers, and (d) all of ModivCare’s current directors and executive officers as a group. Except as otherwise specified, the named beneficial owner has sole voting and investment power with respect to the shares and the address for each beneficial owner of more than 5% of our Common Stock, director, director nominee and named executive officer is: c/o ModivCare Inc., 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237.



Name of Beneficial Owner	No. of Shares of Common Stock Beneficially Owned (1)	Percent of Class (1)

5% or greater security holders
Coliseum Capital Management, LLC (2)	2,982,751	21.0	%
BlackRock, Inc. (3)	2,002,136	14.1	%
The Vanguard Group (4)	905,381	6.4	%
Neuberger Berman Group LLC (5)	902,564	6.4	%
Fuller & Thaler Asset Management, Inc. (6)	866,173	6.1	%
Millennium Management LLC (7)	797,918	5.6	%
Silvercrest Asset Management Group LLC (8)	709,360	5.0	%
Directors
Todd J. Carter (9)	14,119	*
David A. Coulter (9)	29,105	*
Garth Graham (9)	3,186	*
Richard A. Kerley (9)	38,240	*
Leslie V. Norwalk (9)	16,172	*
Rahul Samant (9)	6,603	*
L. Heath Sampson (10)	19,041	*
Christopher S. Shackelton (11)	2,982,751	21.0	%
Frank J. Wright	19,105	*
Non-Director Named Executive Officers
Barbara Gutierrez (12)	—	—
Anne Bailey (13)	7,859	*
Ilias Simpson (14)	2,554	*
Henry Toledo (15)	—	—
All current directors and executive officers as a group (15 persons)	3,139,360	22.1	%

* Less than 1 %

1. The securities “beneficially owned” by each stockholder are determined in accordance with the definition of “beneficial ownership” set forth in the regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, they may include securities to which the stockholder has or shares voting or investment power or has the right to acquire voting or investment power within 60 days of the Record Date. Beneficial ownership may be disclaimed as to certain of the securities. As of the Record Date there were 14,210,882 shares of the Common Stock outstanding (including 15,948 restricted shares that do not have the right to vote). The Common Stock is the only outstanding class of capital stock of the Company with voting rights. The Common Stock votes as a single class, with each share of Common Stock entitled to one vote on each matter presented at the Annual Meeting.


8			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Voting Securities of Certain Beneficial Owners and Management

2. This information is based on ownership information reported in the Schedule 13D/A filed with the SEC on September 18, 2023 by Coliseum Capital Management, LLC (“CCM”), Coliseum Capital, LLC (“CC”), Coliseum Capital Partners, L.P. (“CCP”), Coliseum Capital Partners II, L.P. (“CCP2”), Adam Gray and Christopher Shackelton (105 Rowayton Avenue, Rowayton, CT 06853) and on the Form 4 filed with the SEC by the same entities and individuals on February 20, 2024. Based on information available in the Schedule 13D/A and the Form 4, the shares are held directly by (a) CCP, an investment limited partnership of which CC is general partner and for which CCM, a Delaware limited liability company, serves as investment adviser, (b) CCP2, an investment limited partnership of which CC is general partner and for which CCM serves as investment adviser, (c) a separate account investment advisory client of CCM (the “Separate Account,” and, collectively with CCP and CCP2, the “Coliseum Stockholders”). CCM, Christopher Shackelton, and Adam Gray each have shared voting and shared dispositive power over 2,982,751 shares, CC has shared voting and shared dispositive power over 2,344,778 shares, CCP has shared voting and shared dispositive power over 2,231,441 shares, CCP2 has shared voting and shared dispositive power over 113,337 shares, and the Separate Account has shared voting and shared dispositive power over 637,973 shares. Christopher Shackelton, the Chairman of our Board, and Adam Gray are managers of and have an ownership in each of CCM and CC and may be deemed to have an indirect pecuniary interest in the shares held by CCP, CCP2 and the Separate Account due to CCM’s right to receive performance-related fees from the Separate Account and CC’s right to receive performance-related fees from CCP and CCP2. Each of Christopher Shackelton, Adam Gray, CCP, CCP2, the Separate Account, CC and CCM disclaims beneficial ownership of these securities except to the extent of that person’s own pecuniary interest therein.

3. This information is based on the Schedule 13G/A filed with the SEC by BlackRock, Inc. (55 East 52nd Street, New York, NY 10055) on January 23, 2024, and includes 16,334 shares with respect to which the reporting person reports having no voting power.

4. This information is based on the Schedule 13G/A filed with the SEC by The Vanguard Group (100 Vanguard Blvd., Malvern, PA 19355) on February 13, 2024, and includes (1) 23,027 shares with respect to which the reporting person reports having shared voting power and (2) 34,567 shares with respect to which the reporting person reports having shared dispositive power.

5. This information is based on the Schedule 13G filed with the SEC by Neuberger Berman Group LLC (“Neuberger”) and Neuberger Berman Investment Advisers LLC (“Neuberger Investment”) (1290 Avenue of the Americas, New York, NY 10104) on February 13, 2024. Neuberger has shared voting power over 866,823 shares and shared dispositive power over 902,564 shares. Neuberger Investment has shared voting power over 862,658 shares and shared dispositive power over 898,083 shares.

6. This information is based on the Schedule 13G/A filed with the SEC by Fuller & Thaler Asset Management, Inc. (411 Borel Avenue, Suite 300, San Mateo, CA 94402) on February 12, 2024, and includes 15,960 shares with respect to which the reporting person reports having no voting power.

7. This information is based on the Schedule 13G filed with the SEC by Millennium Management LLC (“Millennium”), Millennium Group Management LLC (“Millennium Group”) and Israel A. Englander (399 Park Avenue, New York, New York 10022) on April 12, 2024, and includes 797,918 shares over which the reporting persons reports each have shared voting and dispositive power.

8. This information is based on the Schedule 13G filed with the SEC by Silvercrest Asset Management Group LLC, Silvercrest L.P. and Silvercrest Asset Management Group Inc. (1330 Avenue of the Americas, 13th Floor, New York, NY 10019) on February 14, 2024 and includes 709,360 shares over which the reporting persons each have shared voting and dispositive power.

9. The shares reported do not include 2,658 unvested restricted stock awards.

10. The shares reported include 14,383 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable. The shares reported do not include 31,305 unvested restricted stock units (“RSUs”), 3,297 unvested stock options or 51,855 unvested Performance Restricted Stock Units (“PRSUs”).

11. Includes shares of Common Stock held by the Coliseum Stockholders (for additional information see (2) above). Christopher Shackelton disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

12. The shares reported do not include 14,707 unvested RSUs or 22,062 unvested PRSUs.

13. The shares reported include 3,936 shares of Common Stock issuable upon the exercise of stock options that are exercisable within 60 days of the Record Date. The shares reported do not include 13,981 unvested RSUs, 7,873 unvested stock options or 16,264 unvested PRSUs.

14. The shares reported include 2,175 shares of Common Stock issuable upon the exercise of stock options that are currently exercisable. Due to the termination of Mr. Simpson’s employment as of May 1, 2024, all unvested options, RSUs and PRSUs held by him will be forfeited in accordance with the terms of his separation agreement and will not vest.

15. The shares reported do not include 22,501 unvested RSUs or 20,916 unvested PRSUs.


Modivcare 2024 Proxy Statement			9


			TABLE OF CONTENTS

Proposal One:
Election of Directors

The Company’s Second Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), provides that the number of directors be between four and eleven, as determined by the Board. The Board currently has established the total number of directors to be nine directors. The size of the Board will be reduced to eight directors in conjunction with the Annual Meeting, however, to eliminate any vacancy that would otherwise have resulted from the expiration of Frank J. Wright’s term as a director at the Annual Meeting, since his role as such will not continue thereafter.

Prior to the 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”), the Board was divided into three classes, which we designated as Classes 1, 2, and 3, with directors serving staggered three-year terms. At the 2023 Annual Meeting, the Company’s stockholders approved a proposal to amend the Certificate of Incorporation to declassify the Board over a three-year period, beginning with the 2023 Annual Meeting, and provide for the annual election of directors upon expiration of their current term. As such, we are in the process of phasing out the classified board structure and all continuing directors, other than the two directors previously classified as Class 1 directors, will be up for re-election at this year’s Annual Meeting for one-year terms expiring at the 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). Beginning with the 2025 Annual Meeting, the declassification of the Board will be complete and all directors will serve one-year terms expiring at the next annual meeting of stockholders.

Under the Company’s Bylaws, to be elected in an uncontested election such as the election at this year’s Annual Meeting, a director nominee must receive more votes cast for such director nominee than cast against such director nominee. In an uncontested election, an incumbent director nominee must submit an irrevocable resignation that will be given effect only if (i) that director receives fewer votes cast for the director than against the director, and (ii) the resignation is accepted by the Board in accordance with the policies and procedures adopted by the Board for such purpose. In the event an incumbent director does not receive more votes cast for the director than against in an uncontested election, the Nominating and Governance Committee will make a recommendation to the Board as to whether to accept or reject the resignation or whether other action should be taken. The Board is required to act on the Nominating and Governance Committee’s recommendation no later than 90 days following certification of the stockholder vote. If any incumbent director does not receive more votes cast for the director’s election than against, the Board will publicly disclose its decision regarding accepting or not accepting a resignation within four business days of reaching its decision.

The Board proposes the election of Todd J. Carter, David A. Coulter, Garth Graham, Leslie V. Norwalk, Rahul Samant, and L. Heath Sampson for one-year terms expiring at the 2025 Annual Meeting. The director nominees were nominated by the Nominating and Governance Committee of our Board, which nomination was confirmed by the Board. Each nominee has consented to serve as a nominee for election to the Board, to be named in the Proxy Statement and to serve as a member of the Board if elected by the Company’s stockholders. Information regarding each nominee is set forth below.

The Board has no reason to believe that the Board’s nominees will be unable to serve or will not serve if elected. If, at the time of the Annual Meeting, any nominee becomes unavailable for any reason for election as a director, the persons entitled to vote as proxy will vote for the election of such substitute(s), if any, as the Board may recommend.

Messrs. Carter, Coulter, Graham, Samant and Sampson and Ms. Norwalk are incumbent directors of the Company, all of whom were previously elected by the stockholders.

Board Recommendation

____

The Board unanimously recommends that the stockholders vote “FOR” the election of Todd J. Carter, David A. Coulter, Garth Graham, Leslie V. Norwalk, Rahul Samant, and L. Heath Sampson as directors of the Company for one-year terms.


10			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Proposal Two

Unless directed otherwise, the persons acting as proxies intend to vote for the election of the listed nominees or, in the event of death, disqualification, refusal or inability of a nominee to serve, for the election of such other person as the Board may recommend in the place of such nominee to fill the vacancy.

The Board unanimously recommends that the stockholders vote “FOR” the election of Todd J. Carter, David A. Coulter, Garth Graham, Leslie V. Norwalk, Rahul Samant and L. Heath Sampson as directors of the Company for the one-year terms.

The following table sets forth information with respect to the director nominees standing for election at the Annual Meeting and the continuing directors as of the Record Date.


Name	Age	Class (1)	Term Expires
Todd J. Carter†	60	3	2024
David A. Coulter†	76		2024
Garth Graham†	50	3	2024
Richard A. Kerley	74	1	2025
Leslie V. Norwalk†	58		2024

Rahul Samant†	58		2024
Christopher S. Shackelton	44	1	2025

L. Heath Sampson†	53		2024

† Director Nominee

1. With the approval of the stockholder’s at the 2023 Annual Meeting, the Board is in the process of being declassified. Class 2 was eliminated at the 2023 Annual Meeting and Class 3 is being eliminated at the 2024 Annual Meeting. Directors previously designated as Class 3 directors are being elected for one-year terms expiring at the next annual meeting of stockholders. At the 2025 Annual Meeting, the declassification will be complete and all directors will stand for election on an annual basis.

The process undertaken by the Nominating and Governance Committee in selecting qualified director candidates is described below under the caption “Corporate Governance—Director Nomination Process—Director Nominee Selection Process.” Certain individual qualifications and skills of our directors that contribute to the Board’s effectiveness as a whole are described in each director’s biography.


Modivcare 2024 Proxy Statement			11


Proposal Two			TABLE OF CONTENTS

Director Nominees


						Todd J. Carter ____ Todd J. Carter is Chairman of Global Technology at Houlihan Lokey. Prior to assuming his role at Houlihan Lokey in October 2021, Mr. Carter served as Chief Executive Officer and Co-Founder of GCA Advisors, LLC (“GCA”), a global independent investment banking firm, since 2008 until GCA was acquired by Houlihan Lokey in October 2021. Mr. Carter also served on the board of directors of GCA. Prior to that, Mr. Carter served as Chairman, President and Chief Executive Officer of Savvian Inc., a global investment banking firm, and Perseus Group, a global asset management and investment banking firm. Prior to 2003, he was President of Robertson Stephens & Company Inc., a global investment banking and asset management firm, and served on the firm’s board of directors. Earlier in his career, Mr. Carter was employed by McKinsey & Company and Smith Barney Inc. Over the past two decades, Mr. Carter has advised on over 1,500 mergers and acquisitions, financings, takeover defenses, leveraged buyouts, divestures, leveraged recapitalizations, joint ventures, stock buybacks, and restructurings and has been actively involved as an early-stage and growth investor, primarily focused on the technology industry. He has invested in more than 100 companies, several of which he co-founded. Mr. Carter has also served on a number of public and private company boards as well as advisory and nonprofit boards. In the nonprofit area, he currently serves on UCSF’s Board of Overseers and the boards of Education SuperHighway and The Conservation Fund. Other selected involvement includes serving as Chairman of OneD Battery Science, a nanowire-material, high-performance battery company, and on advisory boards such as Foresite Capital and Victory Park Capital. Mr. Carter received a bachelor’s degree from the University of Texas and a master of business administration degree from Harvard Business School. Mr. Carter brings to the Board global investment banking experience, including his service as founder and chief executive officer of a large independent global investment bank, and his extensive financial expertise and experience in the transaction advisory industry, as well as a broad span of expertise in the financial advisory and mergers and acquisitions sectors.

Board Committees: Compensation Committee member

Director Since: 2016


12			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Proposal Two


						David A. Coulter ____ Mr. Coulter is a Special Limited Partner of Warburg Pincus LLC, a global private equity firm focused on growth investing. During the past 12 years, he served in various roles at Warburg Pincus, including Vice Chairman as well as Managing Director and senior advisor focused on the firm’s financial services investment activities. Prior to that, Mr. Coulter held a series of positions at J.P. Morgan Chase and was a member of its Office of the Chairman. He also served as Chairman and Chief Executive Officer of Bank of America Corporation. Mr. Coulter is currently a director of Warburg Pincus Capital Corporation I-B (NYSE:WPCB), a publicly traded special purpose acquisition corporation, and Varo, Inc., a digital bank and financial services company. He is also a board member of Innovu, American Prairie Reserve, Carnegie Mellon University, Third Way, the Northern California Asia Society, and a board member Emeritus at Lincoln Center. He previously served as a director of Triton International Ltd. (NYSE:TRTN), a publicly traded global intermodal container leasing company, from 2015 until 2021. Mr. Coulter received a bachelor’s degree and master’s degree from Carnegie Mellon University, and currently serves as Chair of the Board of Trustees. Mr. Coulter’s experiences as both a senior executive of publicly traded financial services corporations, and as a director of public and private companies, provides the Board with extensive executive experience with regard to matters of interest to financial institutions, including risk, compensation, corporate governance and mergers and acquisitions.

Board Committees: Nominating and Governance Committee member

Director Since: 2016


						Leslie V. Norwalk ____ Since September 2007, Ms. Norwalk has served as Strategic Counsel to Epstein Becker & Green, P.C. From 2001 to 2007, Ms. Norwalk served the Bush Administration in the Centers for Medicare & Medicaid Services (CMS). From 2006 to 2007, she was the Acting Administrator, where she managed the operations of federal health care programs, including Medicare and Medicaid. For the four years prior to that position, she was the agency’s Deputy Administrator. Prior to serving the Bush Administration, Ms. Norwalk practiced law with Epstein Becker & Green, P.C. where she advised clients on a variety of healthcare policy matters. She also served the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk is currently a director on the public company boards of NuVasive Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Arvinas Inc., a clinical-stage biopharmaceutical company. She also serves as an Advisor to several private equity funds. She received a bachelor's degree from Wellesley College and a juris doctor degree from George Mason University School of Law. Ms. Norwalk’s significant healthcare regulatory and policy expertise, including her experiences with the Bush Administration on Medicare and Medicaid matters, provides healthcare industry expertise to the Board. Ms. Norwalk will be able to help guide the Company’s strategy, particularly as the healthcare regulatory environment continues to evolve.

Board Committees: Chairperson of the Nominating and Governance Committee, Audit Committee member

Director Since: 2015


Modivcare 2024 Proxy Statement			13


Proposal Two			TABLE OF CONTENTS


						Garth Graham, MD ____ Garth Graham, MD, currently serves as Director and Global Head of Healthcare and Public Health for Google and YouTube at Alphabet, Inc. Previously, he was Chief Community Health Officer at CVS Health Corporation from 2018 until 2020. Dr. Graham was also President of the Aetna Foundation from 2013 until 2019, as well as Vice President of Community Health at Aetna, Inc. from 2017 until its acquisition by CVS Health Corporation in 2018. Prior to that, he served as Assistant Dean of Health Policy and Chief of Health Services Research at University of Florida’s Department of Medicine, and as Attending Physician at The Massachusetts General Hospital. Dr. Graham started his career serving in two U.S. administrations as U.S. Deputy Assistant Secretary for Health, where he led the development of the federal government’s first national health disparities plan. He is an elected member of the National Academy of Medicine and serves on several boards, including: the National Heart, Lung, and Blood Institute Advisory Council; the Institute of Medicine Board on Population Health; and the Board of the National Quality Forum. Dr. Graham is currently a director on the board of Science Applications International Corp. (NYSE: SAIC), a technology-driven company focused on digital transformation across multiple markets. He graduated with a Bachelor of Science in Biology from Florida International University, a Master of Public Health from Yale School of Public Health, and a Doctor of Medicine from Yale University’s School of Medicine. Dr. Graham has approximately two decades of extensive healthcare experience, with an emphasis on community and public health, which provides the Board with deep insight into healthcare administration and policy. Dr. Graham helps guide the Company’s strategy, particularly in the area of social determinants of health.

Board Committees: Nominating and Governance Committee member

Director Since: 2021


						Rahul Samant ____ Rahul Samant currently serves as Chief Information Officer of Delta Air Lines, Inc., a position he has held since 2016. Mr. Samant also serves as Executive Vice President of Delta Air Lines, Inc., a position he has held since 2018, and previously served as Senior Vice President from 2016 until 2018. Prior to that, he was Chief Digital Officer and Global Head of Application Development and Management at American International Group, Inc. and held various technology leadership roles at Bank of America Corporation, including: Chief Information Officer; Head of Technology and Operations for Global Wealth and Investment Management; and Manager and Director of Fixed Income Securities Technology. Mr. Samant commenced his career at Unisys Ltd. He graduated with a Bachelor of Science in Electronics Engineering from University of Mumbai and a Master of Business Administration from Wake Forest University. Mr. Samant’s extensive leadership experience, which spans over 30 years, provides the Board with important technological and operational expertise.

Board Committees: Audit Committee member and Compensation Committee member

Director Since: 2021


14			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Proposal Two


						L. Heath Sampson ____ L. Heath Sampson has served as the Company’s President and Chief Executive Officer since July 27, 2022 and as the Company’s Former Chief Financial Officer from February 26, 2021 through September 2023. Mr. Sampson has nearly three decades of executive and financial leadership experience across a range of private and publicly traded companies. Most recently he served, beginning in April 2015, as Chief Executive Officer of Advanced Emissions Solutions, Inc., an environmental solutions provider to companies in coal-fired power generation, municipal water and other industries, where he orchestrated a successful company turnaround and transformation, after having served there from August of 2014 as Chief Financial Officer and Treasurer. Prior to that, he held Chief Financial Officer roles at private equity-owned Square Two Financial and within key business units at First Data Corporation. He began his career in auditing and business consulting at Arthur Andersen. Mr. Sampson graduated from the University of Denver with a Bachelor of Business Administration degree in Accounting and a Master of Accountancy degree. Mr. Sampson’s significant leadership experience across a variety of industries coupled with his background in auditing and business consulting are particularly relevant to Mr. Sampson’s service on the Board. Further, as the only Board member who is also a member of the Company’s management team, Mr. Sampson provides management’s perspective in Board discussions about the operations and strategic direction of the Company.

Director Since: 2022


Modivcare 2024 Proxy Statement			15


Proposal Two			TABLE OF CONTENTS

Continuing Directors


						Richard A. Kerley ____ Mr. Kerley served as the Senior Vice President, Chief Financial Officer and member of the board of directors of Peter Piper, Inc., a privately held pizza and entertainment restaurant chain, from November 2008 to December 2014, when he retired. From July 2005 to October 2008, Mr. Kerley served as the Chief Financial Officer of Fender Musical Instruments Corporation. From June 1981 to July 2005, Mr. Kerley was an audit partner with Deloitte & Touche LLP. Prior to becoming a partner at Deloitte & Touche, Mr. Kerley served as an audit manager and staff accountant from August 1971 to June 1981. Mr. Kerley also serves on the board of Cavco Industries, Inc., one of the largest producers of manufactured homes in the United States, and served on the board of The Joint Corp., a publicly traded operator, manager and franchisor of chiropractic clinics from September 2015 until June 2019. He received a bachelor’s degree in accounting from Marshall University in 1971. Mr. Kerley served as a senior financial executive with experience in a variety of operational issues, financial budgeting, planning and analysis, capital investment decisions, mergers and acquisitions, operational and financial controls, internal and external reporting, financings and public offerings and filings with the SEC. This strong financial background provides the Board with financial expertise, including an understanding of financial statements, finance, capital investing strategies and accounting.

Board Committees: Chairperson of the Compensation Committee and Chairperson of the Audit Committee

Director Since: 2010


						Christopher S. Shackelton ____ Mr. Shackelton was appointed Chairman in 2012 and served as Interim CEO in 2015. Mr. Shackelton is managing partner and co-founder of Coliseum Capital Management, a private investment firm that invests with a long-term orientation. Previously, Mr. Shackelton worked at Watershed Asset Management and Morgan Stanley & Co. Mr. Shackelton also serves as Chairman of Lazydays Holdings, Inc., an operator of recreational vehicle dealerships, and on the Board of Directors of Universal Technical Institute, a technical training school for the transportation industry and Gildan Activewear Inc., a manufacturer of basic apparel, as well as, from time to time, private companies. Mr. Shackelton was previously Chairman of Rural/Metro Corp, an emergency ambulance company, from December 2010 to June 2011, and Chairman of Medalogix, LLC, a healthcare data analytics company, from August 2014 to May 2021, and served on the boards of BioScrip Inc., an infusion services company, from March 2015 to August 2019, LHC Group Inc., a nursing care company, from November 2012 through August 2017, Advanced Emissions Solutions Inc., an environmental solutions provider to companies in coal-fired power generation, municipal water, and other industries, from August 2014 through May 2016, and Interstate Hotels Inc., a global hotel management company, from February 2009 through March 2010. Mr. Shackelton is actively involved in multiple charitable organizations. Mr. Shackelton received a bachelor's degree in Economics from Yale College in 2001. Mr. Shackelton's experience creating stockholder value for a wide range of companies provides the Board with valuable business leadership and strategic focus. Mr. Shackelton brings financial and investing experience from other public company boards on which he led mergers and acquisitions, financings, restructurings and other initiatives. Furthermore, Mr. Shackelton's in-depth knowledge of the healthcare industry is particularly beneficial to the Board.

Chairman of the Board

Director Since: 2012


16			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Proposal Two

Non-Director Executive Officers

The following is a brief summary as of the Record Date of the background of each executive officer who is not a director:


						Anne Bailey ____ Anne Bailey was appointed President of ModivCare’s Home division in March 2023. She brings over twenty-five years of executive leadership experience in the healthcare industry, including payor and revenue strategy, insurance, and communications. Ms. Bailey was most recently a senior executive and Group Vice President at DaVita, a fortune 250 healthcare company from 2014 until March 2023. Prior to that she was a Vice President at DaVita where she was also a founding member of DaVita’s Power of Women group and led DaVita’s community giving for many years. Ms. Bailey also has experience working with lawmakers to advance healthcare policies. Prior to DaVita, Ms. Bailey was at Bain & Company, where she led consulting teams focused on domestic and international growth strategies. Ms. Bailey has served as President of the Chronic Disease Coalition and sits on the boards of CU Denver Business School, City Year Denver (emeritus), Amp the Cause, and OI Infusion. Ms. Bailey holds a bachelor’s degree from the University of California, San Diego, a Master of Science degree in information systems from the University of Colorado, and a Master of Business Administration degree from the Wharton School of the University of Pennsylvania.

Title: President, ModivCare Home

Age: 51


						Barbara Gutierrez ____ Barbara Gutierrez has served as the Chief Financial Officer since September 2023. Ms. Gutierrez has more than thirty years of experience in executive and financial leadership roles, with a deep background in the healthcare services industry. Ms. Gutierrez also has expertise with high-growth companies and has led transformational business initiatives. Prior to joining ModivCare, Ms. Gutierrez served as CFO at InnovAge, a public company that is one of the largest Program of All-Inclusive Care (PACE) providers in the country, from 2017 until July 2023. She continued to serve in a transitional role as a Senior Advisor at InnovAge from July 2023 until September 2023. Previously, Ms. Gutierrez served as CFO and Chief People Services Officer for Hero Practice Services, a practice management company focused on underserved children. She also previously held senior leadership roles with Strad Energy Services Ltd., Jones Knowledge Group, PhyCor and HealthOne (HCA). Ms. Gutierrez, a certified public accountant and chartered global management accountant, graduated with a B.S. in Accounting from the University of Denver.

Title: Chief Financial Officer

Age: 61


Modivcare 2024 Proxy Statement			17


Proposal Two			TABLE OF CONTENTS


						Jessica Kral ____ Jennifer Kral has served as the Chief Information Officer since June 2023. Ms. Kral has more than twenty-five years of leadership experience, with more than eight years as an executive leading diverse, global IT teams. Prior to joining ModivCare, Ms. Kral served as the SVP Strategy and Transformation for Optum Health Technology from June 2021 to May 2023 and served as the SVP and CIO Business Enablement and Technology for Optum Home & Community from May 2018 to June 2021. In addition, she served as the CIO at UnitedHealthcare and worked as an executive in the IT group for UnitedHealth Group. Ms. Kral, graduated with a BBA in Marketing, Business Finance from University of Wisconsin-Eau Claire and holds an Executive and Professional Coaching Certificate from the University of Texas at Dallas.

Title: Chief Information Officer

Age: 50


						Rebecca Orcutt ____ Rebecca Orcutt has served as the Senior Vice President, Chief Accounting Officer since August 2022. Ms. Orcutt has more than fifteen years of experience in the financial sector, with expertise encompassing a wide range of areas including Securities and Exchange Commission (SEC) reporting and policy, technical accounting, compliance with the Sarbanes-Oxley Act, as well as involvement in merger and acquisition (M&A) activities, and integrations of business combinations. Ms. Orcutt joined ModivCare in January 2021, where she initially held the position of Vice President, Financial Reporting and Accounting. Previously, she worked for over a decade in audit and assurance at KPMG LLP. Ms. Orcutt, a certified public accountant, graduated with a B.S. and a Master of Accountancy from the University of Denver.

Title: Senior Vice President, Chief Accounting Officer

Age: 38


18			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Proposal Two


						Henry Toledo ____ Henry Toledo has served as the Chief People Officer since September 2023. Mr. Toledo has more than thirty years of experience in human resources, operations, and strategy. Prior to joining ModivCare, Mr. Toledo was Chief People Officer for Valet Living from January 2017 until August 2023. Previously, Mr. Toledo was Global Head of Learning, Talent, and Performance Operations at Citigroup and served as Division Vice President and General Manager of Automatic Data Processing’s Recruiting Technology business. Earlier in his career, he worked as an HR leader at WellCare Health Plans and Aramark. Mr. Toledo graduated with a Master’s degree in Management from Temple University, a Bachelor’s degree in Human Resource Management from Georgia State University, and holds an Artificial Intelligence: Business Strategy and Applications certificate from University of California, Berkeley, HAAS School of Business in addition to being a graduate from the Wharton School’s Advanced Management program.

Title: Chief People Officer

Age: 52


Modivcare 2024 Proxy Statement			19


			TABLE OF CONTENTS

Corporate Governance

Board Leadership Structure

The Board recognizes that one of its key responsibilities is to evaluate and determine its optimal leadership structure so as to provide independent oversight of management. The Board understands that there is no single, generally accepted approach to providing Board leadership and recognizes that, depending on the circumstances, other leadership models might be appropriate. Accordingly, the Board periodically reviews its leadership structure.

The Board has determined to separate the roles of CEO and Chairman of the Board between two individuals. The Board believes this leadership structure is appropriate because it strengthens the Board’s independence and enables the CEO to focus on the management of our business.

Independence of the Board

The Board believes that independence depends not only on our directors’ individual relationships, but also on the Board’s overall attitude. Providing objective, independent judgment is at the core of the Board’s oversight function. Under our corporate governance guidelines, the Board, with the assistance of legal counsel and the Nominating and Governance Committee, uses the current standards for “independence” established by NASDAQ to evaluate any material relationship a director may have with the Company to determine director independence. A director is not considered “independent” unless the Board affirmatively determines that the director has no material relationship with the Company or any subsidiary in the consolidated group (other than as a director of ModivCare or one of our consolidated subsidiaries). Any relationship that falls below a threshold set forth by the standards for “independence” established by NASDAQ and our corporate governance guidelines, or is not required to be disclosed under applicable SEC rules, is automatically deemed to be an immaterial relationship. Our Board has affirmatively determined that all directors other than Mr. Sampson are independent directors. Stacy Saal, who served as a director in fiscal year 2023 until her departure from the Board in October 2023, also qualified as an independent director while serving on the Board.

The Board’s Role in Risk Oversight

The Board has an active role, as a whole and at the committee level, in overseeing management of the Company’s risks. The Board regularly reviews information regarding the Company’s credit, liquidity and operations, as well as the risks associated with each. The Company’s Compensation Committee is responsible for overseeing the management of risks relating to the Company’s executive compensation plans and arrangements. The Audit Committee oversees management of financial risks as well as the Company’s information technology, data privacy and cybersecurity risks. The Nominating and Governance Committee manages risks associated with the independence of the Board, potential conflicts of interest as well as legal and regulatory compliance. The Audit Committee and the Nominating and Governance Committee jointly oversee the Company’s ESG and climate-related risks, with the Audit Committee focusing on such matters that relate to financial reporting or processes that could have a material impact on the Company’s operations, financial statements, or reporting obligations and the Nominating and Governance Committee focusing on such matters that relate to governance. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire Board is regularly informed through attendance at committee meetings or committee reports about such risks. In addition, members of senior management regularly provide reports to the Board about their respective areas of responsibility and any related risks. These reports include actions taken by senior management to monitor and control such risks.

Compensation Risks

Prudent risk management is necessary to deliver long-term, sustainable stockholder value. The Compensation Committee believes that the Company’s executive compensation program supports the objectives described below without encouraging inappropriate or excessive risk-taking. In reaching this conclusion, the Compensation Committee considered in particular the following attributes and risk mitigation features of our compensation program:

• our program’s emphasis on long-term, equity-based compensation discourages risk-taking that produces short-term results at the expense of building long-term stockholder value;

• the maximum payout levels for bonuses and equity-based compensation are capped by the Compensation Committee;

• the Compensation Committee can exercise negative discretion to reduce annual cash incentive compensation payments;

• the Compensation Committee uses an independent compensation consultant that performs no other services for the Company, except at the direction of the Compensation Committee;


20			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Corporate Governance

• the Compensation Committee has the authority to make retroactive adjustments to incentive compensation pursuant to the Company’s clawback policy; and

• the Compensation Committee reviews, in consultation with the Company’s outside compensation advisors, data contained in our peers’ proxy filings, to arrive at a compensation program that is consistent with our peers and aligns with the interests of the Company’s stockholders.

Communication with the Board

Stockholders may communicate with the Board as a whole, the non-management directors or any individual director, by sending a letter to ModivCare Inc., c/o Corporate Secretary, 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237. In the letter, the stockholder must identify him or herself as a stockholder of ModivCare. The Corporate Secretary may require reasonable evidence that the communication is being made by or on behalf of a stockholder before the communication is transmitted to the individual director or to the Board as a whole. Depending on the subject matter, the Corporate Secretary will either (i) promptly forward to the Chairperson of the Audit Committee and the General Counsel any communication alleging legal, ethical or compliance issues by management or any other matter deemed by the Corporate Secretary to be potentially material to the Company or (ii) not forward to the Board, any committee or any director, any communications of a personal nature or not related to the duties of the Board, including, without limitation, junk mail and mass mailings, business solicitations, routine customer service complaints, new product or service suggestions, opinion survey polls or any other communications deemed by the Corporate Secretary to be immaterial to the Company.

Meetings of the Board of Directors and Committees

During fiscal year 2023, the Board held ten meetings. In addition, during fiscal year 2023, the Audit Committee held ten meetings, the Compensation Committee held six meetings, and the Nominating and Governance Committee held four meetings. During fiscal year 2023, all directors attended at least 75% of the aggregate of the meetings of our Board and of the Committees on which each director served.

Members of the Board and its committees also consulted informally with management from time to time and acted at various times by written consent without a meeting during fiscal year 2023. Additionally, the independent members of the Board met in executive session regularly without the presence of management.

The Board has an internal policy that all of the directors should attend (either telephonically or in person) the annual meeting of stockholders, absent exceptional cause. All of the directors who were directors at the time of the meeting attended the 2023 annual meeting of stockholders.

Committees of the Board of Directors

The Board has three separately designated standing committees: the Audit Committee, the Compensation Committee and the Nominating and Governance Committee, each as described below. The Audit, Compensation, and Nominating and Governance Committees are each governed by a written charter approved by the Board. A copy of each committee’s charter is available on our website at www.ModivCare.com/governance. ModivCare intends to disclose any amendments to these charters required by the SEC or listing standards of NASDAQ at the same location on our website. The information contained on our website is not part of, and is not incorporated by reference in, this Proxy Statement or any other report we file with or furnish to the SEC.


Audit Committee			The Audit Committee currently consists of Mr. Kerley (Chairperson), Ms. Norwalk, Mr. Samant and Mr. Wright.

The primary function of our Audit Committee is to assist our Board in fulfilling its responsibility to oversee management’s conduct of our financial reporting process, including review of our financial reports and other financial information, our system of internal accounting controls, the qualifications and independence of our independent auditors, the performance of our internal audit staff and independent auditors, and, together with our Nominating and Governance Committee, our compliance with legal and regulatory requirements as well as our ESG efforts and climate-related risks. Our Audit Committee has sole authority to appoint, retain, compensate, evaluate and terminate our independent auditors and to approve all engagement fees and terms for our independent auditors. In addition, our Audit Committee provides oversight to the Company’s information security and data privacy programs.


Modivcare 2024 Proxy Statement			21


Corporate Governance			TABLE OF CONTENTS

The Board has determined that each member of the Audit Committee is independent as defined by the applicable NASDAQ listing standards and applicable SEC rules. The Board has determined that Mr. Kerley is an “audit committee financial expert” as defined in applicable SEC rules. As discussed above, Mr. Wright’s term as a director is expiring at the Annual Meeting and, therefore, he will no longer be a member of the Audit Committee following the Annual Meeting.


Compensation Committee			The Compensation Committee currently consists of Mr. Kerley (Chairperson), Mr. Carter and Mr. Samant.

The primary function of our Compensation Committee is to assist our Board in discharging its responsibilities relating to compensation of our executives. These responsibilities include reviewing our general compensation philosophy for executive officers, overseeing the development and implementation of compensation programs for executive officers and reviewing compensation levels, including incentive and equity-based compensation, for executive officers, all other employees, directors and Board committee members. Our Compensation Committee determines and approves compensation for our executive officers and administers our incentive and equity-based compensation plans. In doing so, it considers recommendations made by our CEO meeting in executive session with the Compensation Committee. Our Compensation Committee also reviews, and makes recommendations to the Board regarding, the compensation of our CEO. Under its charter, the Compensation Committee may, in its discretion, form and delegate all or a portion of its authority, duties and responsibilities to one or more subcommittees or to an officer of the Company (so long as such officer does not decide his or her own compensation).

In 2023, the Compensation Committee continued the engagement of an independent compensation consultant, Meridian Compensation Partners, LLC (“Meridian”), a nationally recognized consulting firm, to review the executive compensation programs (including executive pay levels) and assist in structuring short-term and long-term incentive programs for executive and operational management. Meridian reports directly and solely to the Compensation Committee. Meridian does not provide any other services to the Company, except at the direction of the Compensation Committee. The Compensation Committee assessed the independence of Meridian pursuant to the applicable rules and concluded that Meridian’s work did not raise any conflict of interest that would prevent it from independently representing the Compensation Committee.

The Board has determined that each member of the Compensation Committee is independent as defined in applicable NASDAQ listing standards.


Nominating and Governance Committee			The Nominating and Governance Committee currently consists of Ms. Norwalk (Chairperson), Mr. Coulter, Dr. Graham and Mr. Wright.

The primary functions of our Nominating and Governance Committee are to establish criteria for selecting new directors, identifying, screening and recruiting new directors, recommending to our Board a slate of director nominees for election at our next annual meeting of stockholders, monitoring legal and regulatory compliance in coordination with our Audit Committee, and develop and recommend to our Board a set of corporate governance principles. The Committee is directed to assist the Board and management in furthering and promoting the Company’s commitment to diversity and inclusion. In addition, the Committee oversees (i) the Company’s corporate responsibility programs relating to, and (ii) management of the Company’s strategies, initiatives, risks, opportunities, and related reporting obligations with respect to the governance of sustainability and other material ESG efforts, including climate-related risks. The Company’s corporate governance principles are set forth in our Corporate Governance Guidelines which can be found on our website at www.ModivCare.com/governance and are available in print to any stockholder who requests a copy by writing to our Corporate Secretary.

The Board has determined that each member of the Nominating and Governance Committee is independent as defined in applicable NASDAQ listing standards. As discussed above, Mr. Wright’s term as a director is expiring at the Annual Meeting and, therefore, he will no longer be a member of the Nominating and Governance Committee following the Annual Meeting.


22			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Corporate Governance

Board Diversity

The matrix below sets forth the self-identified gender identity and demographic diversity attributes of each of our directors as of April 26, 2024. Please see “Information About Director Nominees,” above, for biographical information on each of our nominees and continuing directors. For information regarding the self-identified gender identity and demographic diversity attributes of our directors as of May 1, 2023, please refer to our proxy statement filed with the SEC on May 1, 2023.

Board Diversity Matrix (as of April 26, 2024)


Board Size:
Total Number of Directors: 9
Gender Identity:	Female	Male	Non-Binary	Gender Undisclosed
Number of directors based on gender identity	1	7	—	1
Number of Directors who identify in any of the categories below:
African American or Black	—	1	—	—
Alaskan Native or American Indian	—	—	—	—
Asian	—	1	—	—
Hispanic or Latinx	—	—	—	—
Native Hawaiian or Pacific Islander	—	—	—	—
White	1	5	—	—
Two or More Races or Ethnicities	—	—	—	—
LGBTQ+	—
Undisclosed	1

Director Nomination Process

Director Qualifications

Nominees for director are selected on the basis of outstanding achievement in their careers and other factors, including: board experience; education; whether they are independent under applicable NASDAQ listing standards and applicable SEC rules; financial expertise; integrity; ability to make independent, analytical inquiries; understanding of the business environment; industry experience; and willingness to devote adequate time to Board and committee duties. The proposed nominee should also be free of conflicts of interest that could prevent such nominee from acting in the best interest of ModivCare and our stockholders. Additional special criteria apply to directors being considered to serve on a particular committee of the Board. For example, members of the Audit Committee must meet additional standards of independence and have the ability to read and understand ModivCare’s financial statements.

Director Nominee Selection Process

In evaluating potential director nominees, including those identified by stockholders, for recommendation to our Board, our Nominating and Governance Committee seeks individuals with talent, ability and experience from a wide variety of backgrounds, and considers attributes such as race, ethnicity, gender, and cultural background when reviewing candidates for our Board and in assessing our Board’s overall composition, in an effort to provide a diverse spectrum of experience and expertise relevant to a diversified business enterprise such as ours. Although we have no minimum qualifications, a candidate should represent the interests of all stockholders, and not those of a special interest group, have a reputation for integrity and be willing to make a significant commitment to fulfilling the duties of a director.


Modivcare 2024 Proxy Statement			23


Corporate Governance			TABLE OF CONTENTS

Our Nominating and Governance Committee will screen and evaluate all recommended director nominees based on the criteria set forth above, as well as other relevant considerations. Our Nominating and Governance Committee will retain full discretion in considering its nomination recommendations to our Board. In identifying, evaluating and nominating individuals to serve as directors, our Board and its Nominating and Governance Committee do not rely on any preconceived guidelines or rules. Rather, our Board and its Nominating and Governance Committee believe that the Company is best served by directors with a wide range of perspectives, professional experiences, skills and other individual qualities and attributes and who come from diverse backgrounds.

To become a nominee, a director must also submit an irrevocable resignation to the Board that is contingent upon (a) such director receiving more votes cast against the director’s election than for the director’s election in the uncontested election, and (b) acceptance of that resignation by the Board in accordance with the policies and procedures adopted by the Board for such purpose. The director must also complete and submit a questionnaire with respect to his or her background and qualifications and execute a written representation and agreement in the form provided by the Company upon request (the “Director/Prospective Director Agreement”).

The Director/Prospective Director Agreement shall require directors and nominees to disclose voting commitments and compensation arrangements and represent that the director or nominee, if elected, would be in compliance with all applicable corporate governance, conflicts of interest, confidentiality, securities ownership and stock trading policies and guidelines of the Company, and also provides for the immediate resignation of a director if such person is found by a court of competent jurisdiction to have breached the Director/Prospective Director Agreement in any material respect.

The Nominating and Governance Committee will consider properly submitted stockholder recommendations for director candidates. Director candidates recommended by stockholders are given the same consideration as candidates suggested by directors and executive officers. The Nominating and Governance Committee has the sole authority to select, or to recommend to the Board, the nominees to be considered for election as a director.

The officer presiding over the annual meeting of stockholders, in such officer’s sole and absolute discretion, may reject any nomination not made in accordance with the procedures outlined in this Proxy Statement and ModivCare’s Bylaws. Under ModivCare’s Bylaws, a stockholder who desires to nominate directors for election at an annual meeting of stockholders must comply with the procedures summarized below. Interested stockholders may review ModivCare’s Bylaws, at no cost, on the SEC’s website, www.sec.gov, as Exhibit 3.5 to ModivCare’s Annual Report on Form 10-K filed with the SEC on February 26, 2024, or by submitting a written request directed to the Company’s Corporate Secretary at the address given in the paragraph below.

Stockholder Nominations

ModivCare’s Bylaws require nominations by stockholders for directors to be elected at a meeting of stockholders which have not previously been approved by the Board must be submitted to our Corporate Secretary in writing, either by personal delivery, nationally recognized express mail or United States mail, postage prepaid, at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237, not earlier than the close of business on the 120th calendar day, and not later than the close of business on the 60th calendar day, prior to the first anniversary of the immediately preceding year’s annual meeting; provided, however, that in the event that no annual meeting was held in the previous year or the annual meeting is called for a date that is more than 30 calendar days earlier or more than 60 calendar days later than such anniversary date, notice by the stockholder in order to be timely must be so delivered or received no earlier than the close of business on the 120th calendar day prior to the date of such annual meeting and not later than the close of business on the later of the 60th calendar day prior to the date of such annual meeting or, if the first public announcement of the date of such annual meeting is less than 70 calendar days prior to the date of such annual meeting, the 10th calendar day following the day on which public disclosure of the date of such annual meeting is first made by the Company.

Each notice of nomination is required to set forth, as to each person whom the stockholder proposes to nominate for election or reelection as a director:

• the name, age, business address and residence address of such person;

• the principal occupation and employment of such person;

• the class and series and number of shares of each class and series of capital stock of the Company which are owned beneficially or of record by such person (which information shall be supplemented not later than ten (10) calendar days after the record date for the meeting to disclose such ownership as of the record date);

• such person’s executed written consent to being named in the proxy statement as a nominee and to serving as a director if elected;


24			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Corporate Governance

• all information relating to such person that would be required to be disclosed in a proxy statement or other filings required to be made with the SEC in connection with the solicitation of proxies for the election of directors in a contested election pursuant to Section 14 of the Exchange Act (or pursuant to any law or statute replacing such section), and the rules and regulations promulgated thereunder;

• a description of all direct and indirect compensation and other material monetary agreements, arrangements and understandings during the past three years, and any other material relationships, between or among such person being nominated, on the one hand, and the stockholder and any Stockholder Associated Person (as defined below), on the other hand, including, without limitation all information that would be required to be disclosed pursuant to Item 404 of Regulation S-K if the stockholder making the nomination and any Stockholder Associated Person were the “registrant” for purposes of such rule and the person being nominated were a director or executive officer of such registrant. A “Stockholder Associated Person” is, with respect to any stockholder, (a) any person controlling, directly or indirectly, or acting in concert with, such stockholder, (b) any beneficial owner of shares of Common Stock of the Company owned of record or beneficially by such stockholder, and (c) any person controlling, controlled by or under common control with such Stockholder Associated Person; and

• a questionnaire regarding his or her background and an executed Director/Prospective Director Agreement.

As to the stockholder giving the notice:

• the name and record address, as they appear on the Company’s stock ledger, of such stockholder and the name and address of any Stockholder Associated Person;

• (a) the class, series and number of shares of each class and series of capital stock of the Company which are, directly or indirectly, owned beneficially and/or of record by such stockholder or any Stockholder Associated Person, documentary evidence of such record or beneficial ownership, and the date or dates such shares were acquired and the investment intent at the time such shares were acquired, (b) any derivative instrument (as defined in the Bylaws) directly or indirectly owned beneficially by such stockholder or any Stockholder Associated Person and any other direct or indirect right held by such stockholder or any Stockholder Associated Person to profit from, or share in any profit derived from, any increase or decrease in the value of shares of the Company, (c) any proxy, contract, arrangement, understanding, or relationship pursuant to which such stockholder or any Stockholder Associated Person has a right to vote any shares of any security of the Company, (d) any short interest (as defined in the Bylaws) indirectly or directly held by such stockholder or any Stockholder Associated Person in any security issued by the Company, (e) any rights to dividends on the shares of the Company owned beneficially by such stockholder or any Stockholder Associated Person that are separated or separable from the underlying shares of the Company, (f) any proportionate interest in shares of the Company or derivative instruments held, directly or indirectly, by a general or limited partnership in which such stockholder or any Stockholder Associated Person is a general partner or, directly or indirectly, beneficially owns an interest in a general partner, and (g) any performance-related fees (other than an asset-based fee) to which such stockholder or any Stockholder Associated Person is entitled based on any increase or decrease in the value of shares of the Company or derivative instruments, if any, as of the date of such notice, including without limitation, any such interests held by members of such stockholder’s or any Stockholder Associated Person’s immediate family sharing the same household (which information, in each case, must be supplemented by such stockholder and any Stockholder Associated Person not later than ten (10) calendar days after the record date for the meeting to disclose such ownership as of the record date);

• a description of all arrangements or understandings between such stockholder and/or any Stockholder Associated Person and each proposed nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by such stockholder;

• any material interest of such stockholder or any Stockholder Associated Person in the election of such nominee, individually or in the aggregate, including any anticipated benefit to such stockholder or any Stockholder Associated Person therefrom;

• a representation from such stockholder as to whether the stockholder or any Stockholder Associated Person intends or is part of a group which intends (1) to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Company’s outstanding capital stock required to elect the person and/or (2) otherwise to solicit proxies in support of the election of such person;

• a representation that such stockholder is a holder of record of stock of the Company entitled to vote at such meeting, that such stockholder intends to appear in person, or by proxy, at the meeting to nominate the person or persons named in the notice;

• whether and the extent to which any agreement, arrangement or understanding has been made, the effect or intent of which is to increase or decrease the voting power of such stockholder or any Stockholder Associated Person with respect to any shares of the capital stock of the Company, without regard to whether such transaction is required to be reported on a Schedule 13D or other form in accordance with Section 13(d) of the Exchange Act or any successor provisions thereto and the rules and regulations promulgated thereunder; and


Modivcare 2024 Proxy Statement			25


Corporate Governance			TABLE OF CONTENTS

• any other information relating to such stockholder or any Stockholder Associated Person that would be required to be disclosed in a proxy statement or other filings required to be made with the SEC in connection with the solicitations of proxies for the election of directors in a contested election pursuant to Section 14 of the Exchange Act (or pursuant to any law or statute replacing such section) and the rules and regulations promulgated thereunder.

In the event that a special meeting of stockholders is called for the election of directors, a stockholder’s nomination must be delivered to the Company not earlier than the close of business on the 120th calendar day prior to the date of the special meeting and not later than the close of business on the later of the 60th calendar day prior to the date of the special meeting, or, if the first public disclosure made by the Company of the date of the special meeting is less than 70 days prior to the date of the special meeting, not later than the 10th calendar day following the day on which public disclosure is first made of the date of the special meeting. The stockholder submitting a notice of nomination with respect to the election of directors at a special meeting must include, in its timely notice, the same information as set forth above.

A majority of the Board may reject any nomination by a stockholder not timely made or otherwise not made in accordance with the terms of the Company’s Bylaws. If a majority of the Board reasonably determines that the information provided in a stockholder’s notice does not satisfy the informational requirements in any material respect, the Corporate Secretary will promptly notify such stockholder of the deficiency in writing. The stockholder will then have an opportunity to cure the deficiency by providing additional information to the Corporate Secretary within such period of time, not to exceed ten (10) days from the date such deficiency notice is given to the stockholder, as a majority of the Board reasonably determines. If the deficiency is not cured within such period, or if a majority of the Board reasonably determines that the additional information provided by the stockholder, together with the information previously provided, does not satisfy the requirements in any material respect, then a majority of the Board may reject such stockholder’s nomination.

Compensation of Non-Employee Directors

In assessing compensation elements and making compensation decisions with respect to our non-employee directors, the Compensation Committee engaged Meridian in 2023 to provide independent advice and recommendations. The non-employee director compensation program (as described below) was approved in 2017, and no changes have been made to the program since that time. The Compensation Committee also relies on information about the director compensation practices of a peer group of companies of similar size to the Company in related industries (see the information under the caption “Executive Compensation—Discussion and Analysis—Approach for Developing the Executive Compensation Program” below), as well as its own judgment and prior experience, in determining director compensation.

As compensation for their service as directors of the Company in 2023 (and consistent with the program approved in April 2017), each non-employee member of the Board received an $85,000 annual cash retainer. For service as committee chairs, the Chairperson of the Audit Committee received an additional retainer of $35,000 and the Chairpersons of the Compensation Committee and Nominating and Governance Committee each received an additional retainer of $20,000. For service as Chairman of the Board, the Chairman of the Board received an additional retainer of $35,000. Members of the Audit Committee, the Compensation Committee and the Nominating and Governance Committees (other than the Chairpersons) received an additional retainer of $15,000, $7,500 and $7,500, respectively. Payment of the retainers were made on a monthly basis in advance of each month of service. The Company’s target value of the equity retainer for non-employee members of the Board in 2023 was $130,000, based on the closing stock price of the Company’s stock on the grant date. Except for certain expense reimbursements noted below, no additional payments were made to non-employee members for participating in Board and committee meetings. Non-employee members of the Board may elect to receive unrestricted shares of Common Stock in lieu of cash compensation. Each of Messrs. Coulter, Samant and Wright and Ms. Saal elected to receive all or a portion of their 2023 director cash compensation in the form of unrestricted shares of Common Stock, which was granted on a quarterly basis on the last trading day of each quarter.

On February 16, 2023, Mr. Carter, Mr. Coulter, Dr. Graham, Mr. Kerley, Ms. Norwalk, Ms. Saal, Mr. Samant and Mr. Wright were each awarded 1,314 restricted stock awards under the Company’s 2006 Long-Term Incentive Plan (the “2006 Plan”) for their annual equity award. On February 16, 2023, Coliseum Capital Partners, L.P. was granted 1,314 stock equivalent units in lieu of an award to Mr. Shackelton. With the exception of Ms. Saal’s awards, all of these awards vested on February 16, 2024, the first anniversary of the grant date. Ms. Saal’s service as a member of the Board of Directors ended in October 2023 and as such, the restricted stock awards granted in connection with her 2023 annual board of director grant were forfeited prior to vesting.

Non-employee directors are also reimbursed for reasonable expenses incurred in connection with attending meetings of the Board and meetings of Board committees.


26			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Corporate Governance

The following table shows for the fiscal year ended December 31, 2023, information with respect to the compensation of our non-employee directors:

2023 Director Compensation Table


Name	Fees Earned ($)	Stock Awards ($) (1)	Total ($)
Todd J. Carter	92,500	129,955	222,455
David A. Coulter	92,500	129,955	222,455
Garth Graham	92,500	129,955	222,455
Richard A. Kerley*	140,000	129,955	269,955
Leslie V. Norwalk*	120,000	129,955	249,955
Stacy Saal (2)	69,375	129,955	199,330
Rahul Samant	100,000	129,955	229,955
Christopher S. Shackelton† (3)	120,000	129,955	249,955
Frank J. Wright	107,500	129,955	237,455

† Denotes Board Chair as of December 31, 2023

* Denotes Committee Chair as of December 31, 2023

1. Represents the aggregate grant date fair value of the stock and stock equivalent units granted in fiscal year 2023. The aggregate grant date fair value of the restricted shares was computed in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718-Compensation-Stock Compensation (“ASC 718”).

The aggregate number of unvested stock awards outstanding for each non-employee director as of December 31, 2023 is shown below, all of which vested on February 16, 2024:


Name			Unvested Restricted Stock Awards
Todd J. Carter			1,314
David A. Coulter			1,314
Garth Graham			1,314
Richard A. Kerley			1,314
Leslie V. Norwalk			1,314
Stacy Saal (2)			—
Rahul Samant			1,314
Frank J. Wright			1,314

The aggregate number of unvested stock equivalent units outstanding for each non-employee director as of December 31, 2023 is shown below, all of which vested on February 16, 2024:


Name			Unvested Stock Equivalent Units
Christopher S. Shackelton (3)			1,314


Modivcare 2024 Proxy Statement			27


Corporate Governance			TABLE OF CONTENTS

2. Ms. Saal’s service as a member of the Board of Directors ended in October 2023, and as such, the RSUs granted in connection with her 2023 annual board of director grant were forfeited prior to vesting. Ms. Saal elected to receive unrestricted shares of Common Stock in lieu of cash compensation for her 2023 director cash compensation and as such, she received her quarterly fee in the form of shares for each quarter through September 30, 2023, prior to her departure from the Board.

3. All of Mr. Shackelton’s compensation for service on the Board inures to the benefit of CCP pursuant to this entity’s policy regarding Mr. Shackelton’s service on the board of companies in which it has an equity interest.

Stock Ownership Guidelines for Non-Employee Directors

Pursuant to our stock ownership guidelines, our non-employee directors are expected to own shares of our Common Stock with a value equal to five times their annual retainer (excluding compensation for board or committee chair, committee member or lead director positions held). Because Mr. Shackelton assigns all of his Board compensation to CCP as described above, he is excluded from these stock ownership guidelines.

The following counts towards meeting the required holding level:

• shares held directly or indirectly;

• shares underlying any vested RSUs held under our equity-based director compensation program;

• any unvested time-based restricted shares or RSUs held under our equity-based director compensation program (calculated on an assumed net after-tax basis); and

• shares owned jointly with or in trust for, immediate family members residing in the same household.

Non-employee directors are not permitted to sell compensatory shares of our Common Stock until they have reached the required holding level, except if such sale is effected to satisfy tax obligations or to pay the exercise price of options. This holding requirement does not apply to shares purchased by a non-employee director in the market or from the Company for cash unless acquired by exercise of a compensatory option. In the event a non-employee director does not achieve his or her holding level set forth above and sells shares of our Common Stock in violation of the stock ownership guidelines, the Board will consider all relevant facts and take such actions as it deems appropriate under the circumstances. All of our non-employee directors were in compliance with our stock ownership guidelines as of December 31, 2023, with the exception of Dr. Graham and Mr. Samant, who joined the Company in 2021 and have not yet met the required holding level.

Delinquent Section 16 Reports

Section 16 of the Exchange Act requires our executive officers, directors and persons who beneficially own more than 10% of a registered class of the Common Stock to file with the SEC initial reports of ownership and reports of changes in ownership of Common Stock and other equity securities of ModivCare.

To the Company’s knowledge, based solely on a review of the copies of such reports filed with the SEC and written representations that no other reports were required, the Company believes that all Section 16 officers, directors and greater than 10% beneficial owners of the Company’s common stock complied with applicable Section 16 requirements during the fiscal year ended December 31, 2023, except for that one Form 4 reporting one transaction for each of Messrs. Coulter, Samant and Wright was filed late.

Family Relationships

There are no family relationships among any of our directors and executive officers.

Certain Relationships and Related Party Transactions

Policy Regarding Certain Relationships and Related Party Transactions

Pursuant to its written charter, the Audit Committee has adopted a Related Person Transaction Policy that, subject to certain exceptions, requires the Audit Committee (or the chair of the Audit Committee in certain instances) to review and either ratify, approve or disapprove all “transactions” with “related persons,” which have the meanings given to such terms in Item 404(a) of Regulation S-K of the Securities Act of 1933, as amended.


28			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Corporate Governance

In determining whether to approve or ratify a transaction with a related person under the policy, the Audit Committee is to consider all relevant information and facts available to it regarding the transaction and take into account factors such as the related person’s relationship to the Company and interest in the transaction (direct or indirect), the terms of the transaction and the benefits to the Company of the transaction. No director is to participate in the approval of a related person transaction for which he or she is a related person or otherwise has a direct or indirect interest.

The Audit Committee reviews and assesses ongoing related person transactions, if any, on at least an annual basis to determine whether any such transactions remain appropriate or should be modified or terminated.

Each year our directors and officers complete Directors’ and Officers’ Questionnaires, which, among other things, are designed to elicit information relating to transactions with the Company in which the officer or director or any immediate family member of such officer or director has a direct or indirect interest. We also make inquiries quarterly of officers and directors to identify any additional related person transactions that have arisen since the last inquiry as a means to ensure all potential transactions subject to the policy are captured. These questionnaires are reviewed by our General Counsel and any such transactions or other related person transactions are brought to the attention of the Audit Committee as appropriate.

Related Party Transactions

Since January 1, 2023, there have been no related party transactions that met the requirements for disclosure in this Proxy Statement.

Compensation Committee Interlocks and Insider Participation

The Compensation Committee consists of Mr. Kerley (Chairperson), Mr. Carter and, beginning in April 2024, Mr. Samant. Ms. Saal also served as a member of our Compensation Committee under her departure from the Board in October 2023. No person who served as a member of the Compensation Committee during the fiscal year ended December 31, 2023 was a current or former officer or employee of ModivCare, or engaged in any transactions with us which was required to be disclosed by regulations of the SEC. None of ModivCare’s executive officers served as a director or member of the compensation committee of another entity, one of whose executive officers served as a member of our Board or as a member of our Board’s Compensation Committee.


Modivcare 2024 Proxy Statement			29


			TABLE OF CONTENTS

Executive Compensation

Compensation Discussion and Analysis

Introduction

This Compensation Discussion and Analysis explains the executive compensation program for the following individuals, who are referred to as the named executive officers (“NEOs”):

• L. Heath Sampson – President, Chief Executive Officer, and Former Chief Financial Officer*

• Barbara Gutierrez – Chief Financial Officer*

• Anne Bailey – President of ModivCare Home*

• Henry Toledo – Chief People Officer*

• Ilias Simpson – Former President of ModivCare Mobility*

* Mr. Sampson has served as Chief Executive Officer since July 2022 and his service as Chief Financial Officer ceased in September 2023. Ms. Gutierrez has served as Chief Financial Officer since September 2023. Ms. Bailey has served as President of ModivCare Home since March 2023. Mr. Toledo has served as Chief People Officer since August 2023. Mr. Simpson served as President of ModivCare Mobility from April 2022 until April 2024, although his employment with the Company is continuing in a transitional role until May 1, 2024.

Executive Summary

Despite the challenging macroeconomic environment which is characterized by high inflation rates, high interest rates, supply chain challenges, labor shortages, volatility in capital markets and growing recession risk and its impact on our business and society at large, the Company continued the evolution of its business and technology that had positive impacts on our clients, transportation providers and members. We also enhanced our executive leadership, resulting in an experienced team with a track record of operational excellence, including the addition of veteran leaders with the addition of Anne Bailey, President of ModivCare Home, Barbara Gutierrez, Chief Financial Officer, Henry Toledo, Chief People Officer, and Jessica Kral, Chief Information Officer. We made progress building for scale through our integration efforts in 2023 which included general ledger and personnel management system integrations and made continued investment in our data analytics capabilities, which we expect to continue in 2024. We maintained our membership at approximately 34 million monthly members in our Mobility segment despite Medicaid redetermination headwinds and we grew our Personal Care caregiver base. We integrated digital workforce resources, including onboarding, training, and scheduling for caregivers and expanded our virtual processes in 2023 which contributed to an increase in our caregiver satisfaction score, resulting in an increase in the number of caregivers.


			We strengthened our senior leadership, and redefined our vision and goals under a talented new executive team.
			We advanced key technology and center of excellence optimization initiatives
2023			We made a strategic investment in innovation to further our data analytics capabilities


30			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

2. The net loss in 2023 is related to a goodwill impairment charge that was recorded during the second quarter of 2023.

Against this challenging macroeconomic environment, the Compensation Committee has utilized four key objectives to continue to engage, retain and motivate the Executive Leadership Team at ModivCare. For 2023, this included enhancing the performance-based aspect of our compensation strategy through the introduction of new structure of performance restricted stock units (“PRSUs”). The structure of PRSUs introduced in 2022 aligned executive performance with Company performance by tying the outcome of these awards to common stock price appreciation target values, in addition to time-based vesting restrictions. The new structure of PRSUs introduced in 2023 was granted with different performance targets to align executive performance with Company performance by tying the vesting of these awards to Adjusted EBITDA and Revenue targets, as applicable to each grant, in addition to time-based vesting restrictions.

The guiding principles of our compensation philosophy are intended to meet the following objectives:


1			Market competitiveness
2			Pay-for-Performance
3			Align with Stockholder Interests
4			Risk Mitigation


Modivcare 2024 Proxy Statement			31


Executive Compensation			TABLE OF CONTENTS

We use market and stockholder driven compensation practices to ensure that there is alignment in pay for performance for our executives.


What we do:						“Double-trigger” change of control provisions
						Emphasize pay for performance
						Maintain a clawback policy that covers both cash and equity compensation and addresses reputational and financial risk as well as risk management failures
						Use an independent compensation consultant
						Limit executive perquisites
						Maintain robust stock ownership guidelines applicable to all of our executive officers and directors
						Provide a significant portion of officer compensation in variable at-risk pay elements
						Conduct competitive benchmarking to understand market-typical officer pay levels and practices


What we do not do:						No “single-trigger” accelerated vesting of equity-based compensation
						No tax gross-ups on executive perquisites
						No short-selling, hedging or pledging of Company securities
						No excessive perquisites
						No trading in Company securities during black-out periods, except under limited circumstances, including Rule 10b5-1 trading plans
						No repricing of stock options without stockholder approval
						No excise tax “gross ups” upon change in control


32			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

The elements of our performance-based compensation program are as follows:



Component of Performance-Based Compensation			Description of Program

Short-Term Incentive Plan (the “STI”)			The STI is designed to provide financial incentive to the executives for achieving in-year goals that are aligned to stockholder value creation. As further described below under “2023 Executive Compensation Program Decisions—Short-Term Incentive Plan,” cash awards were granted under the STI to our NEOs based on 2023 performance.
Long-Term Incentive Program (the “LTI”)			The LTI is designed to align the eligible executives’ incentives with our stockholders’ interests to achieve increases in our stock value. As further described below under “2023 Executive Compensation Program Decisions—Long-Term Incentive Program,” equity awards were granted under the LTI to each of our NEOs in 2023.

STI Determinations

As further described below under “2023 Executive Compensation Program Decisions—Short-Term Incentive Plan,” the Compensation Committee utilized Compensation Adjusted EBITDA, a non-GAAP financial measure that is reconciled to its most directly comparable GAAP financial measure, net income, in Appendix A to this Proxy Statement, as the financial measure against which to determine whether payouts would be made to executives under the 2023 STI. The Compensation Committee chose to use Compensation Adjusted EBITDA, among other reasons, to motivate the executives to manage, to the extent reasonably practicable, the Company’s operating expenses to the amounts that were included in the Company’s Board approved 2023 operating budget. For the 2023 STI, the Compensation Committee determined that Compensation Adjusted EBITDA would begin with the baseline target of publicly disclosed EBITDA, rather than publicly disclosed Adjusted EBITDA as the baseline, and adjust publicly disclosed EBITDA by certain items that were not included in the Company’s Board approved 2023 operating budget.

LTI Determinations

As further described below under “2023 Executive Compensation Program Decisions—Long-Term Incentive Program,” equity awards were granted under the LTI in 2023 to each of Messrs. Sampson, Simpson and Toledo and Mses. Gutierrez and Bailey.

Stockholder Say-on-Pay and Company Response

In establishing and recommending 2023 compensation for the NEOs, the Compensation Committee considered the results of the Say-on-Pay vote at the 2023 annual meeting of stockholders. At the 2023 annual meeting, our stockholders approved our executive compensation for the 2022 fiscal year with the affirmative vote of approximately 99% of shares present in person or represented by proxy and entitled to vote on the proposal. Our Board recognizes that executive compensation is important to stockholders and takes this into account when reviewing the compensation program throughout the year. We believe that we have established a performance-based compensation plan that aligns the compensation paid to NEOs with value delivered to stockholders.

Discussion and Analysis

Executive Compensation Philosophy

ModivCare’s compensation philosophy is designed to attract, incentivize and retain highly talented individuals with diverse backgrounds and experience who are committed to our core values and our goal of balancing mission and margin.

The guiding principles for our compensation philosophy are:

• Offer Market Competitive Compensation - Aggregate total direct compensation (base salary, variable pay and long-term incentive) should be near the market median (if affordable) and allows company and/or individual performance to drive actual compensation up or down, including above target pay at the market median when performance warrants it;

• Pay-for-Performance - There should be a strong link between our business strategy, the performance metrics in our short-term and long-term incentive programs, and the business results that drive stockholder value;

• Align with Stockholder Interests - A significant portion of pay should be performance-based, with the percentage of total pay tied to performance increasing proportionally with a leader’s level of responsibility, and the compensation policies should include an opportunity for, and a requirement of, significant equity ownership intended to align the interests of NEOs and stockholders; and


Modivcare 2024 Proxy Statement			33


Executive Compensation			TABLE OF CONTENTS

• Risk Mitigation - Financial risk should be managed through sound plan design and decision-making, with the Compensation Committee and its independent compensation consultant reviewing our executive compensation plans and programs for inappropriate risk on an ongoing basis.

Looking forward to 2024, we are further enhancing the performance-based aspect of our compensation strategy by launching a new structure of PRSUs that aligns the performance of executives to the Adjusted EBITDA goals of the Company and the Company’s Relative Total Shareholder Return (RTSR), in addition to time-based vesting restrictions. This structure is built toward the Company’s performance goals while also aligning executive compensation with the Company’s performance in relation to its peers.

2023 Compensation Components

The specific components of the 2023 compensation program for NEOs were as follows:


Component	Description	Purpose

Base Salary	Fixed cash component established upon hire (and adjusted from time to time) based on overall skills and experience.	Provide competitive fixed compensation to attract and retain executive talent, reward individual performance, and address market competitiveness.


Short-Term Incentive Plan (the “STI”)	The STI for our NEOs is based on Company financial and NEO individual performance metrics, as described further below.	Provide financial incentive to the executives to reward them for achieving specific strategic, organizational, financial and individual goals that are intended to improve stockholder value.


Long-Term Incentive Program (the “LTI”)	The LTI provides for the grant to the eligible NEOs of a combination, depending on the executive, of stock options, restricted stock units (RSUs) and performance restricted stock units (PRSUs). Our stock options provide NEOs with the right to purchase Company stock after a specified date, at an exercise price equal to the closing market price on the grant date. Our restricted stock units provide NEOs with the right to receive shares of Company common stock on a specified date in the future after vesting occurs. RSUs retain the right to receive dividends on the underlying shares, however such dividends are not paid until the RSUs vest. RSUs do not provide voting rights. Our performance restricted stock units provide NEOs with the right to receive shares of Company common stock based on the achievement of certain performance targets, in addition to time-based vesting restrictions. In 2023, the performance aspect of the PRSUs was tied to Adjusted EBITDA and Revenue goals set by the Company, as applicable, depending on the executive and the timing of the award.	Provide motivation to align the executives’ incentives with our stockholders’ interests in achieving increases in our stock value. The combination of stock options, RSUs and PRSUs furthered the Compensation Committee’s objectives of directly aligning executive compensation with stockholder interests, with (1) the stock option component motivating performance through stock price appreciation (i.e., stock options have no value if stock price does not appreciate), (2) RSUs providing incentives for long-term retention of key executives and (3) PRSUs motivating performance through achievement of Adjusted EBITDA and Revenue goals, as applicable, and providing incentives for long-term retention.


Benefits and Perquisites	We provide benefits generally available to all employees and we provide additional benefits for NEOs. Perquisites for NEOs relate to enhanced insurance and other non-cash benefits. See the discussion below under the caption “—Benefits and Perquisites” for further detail.	Provide a competitive level of employee benefits; aids in attraction and retention of key executives.


Post-Termination Compensation	NEOs are eligible for payments post-termination, as specified below under the caption “—Potential Payments Upon Termination or Change in Control.”	Provide an appropriate level of payment in the event of a termination in connection with a change in control or certain other termination events in order to motivate executives to put the Company’s long-term objectives ahead of their own.


Other Policies	• Stock Ownership Guidelines • Clawback Policy • Anti-Hedging / Anti-Pledging Policy	Enhance alignment between executive and stockholder interests.


34			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Approach for Developing the Executive Compensation Program

The compensation of our CEO is determined by the Compensation Committee, subject to the approval of the full Board excluding our CEO. Our CEO annually reviews the performance of each NEO, other than himself, relative to the annual performance goals established for the year. Our CEO then makes recommendations to the Compensation Committee with respect to all aspects of the compensation of the other NEOs who report directly to him, but the Compensation Committee exercises discretion and has the final decision with respect to executive compensation.

In 2023, the Compensation Committee engaged Meridian to assess the competitiveness of pay for the executive officers and provide independent advice and recommendations to the Compensation Committee regarding executive compensation. In order to avoid conflicts of interest, Meridian only does work authorized by the Compensation Committee. The Compensation Committee annually reviews Meridian’s independence as contemplated by the Compensation Committee’s charter and applicable NASDAQ rules, and determined in 2023 that there were no conflicts of interest.

We believe it is appropriate for NEO pay to be competitive with the market for comparable executives. To achieve this objective, we assess market data for a peer group of companies established by the Compensation Committee, with the assistance of its compensation consultant, from time to time. The peer group chosen for purposes of the 2023 compensation decisions is provided below. The group is composed of 16 health services related companies that were comparable to us in terms of business mix and size (e.g., revenue, EBITDA, and market capitalization) when it was chosen for 2023.


2023 Peer Group
Acadia Healthcare Company, Inc.	Brookdale Senior Living Inc.	Hanger, Inc.	Option Care Health, Inc.
Addus HomeCare Corporation	Chemed Corporation	Healthcare Services Group, Inc.	Select Medical Holdings Corporation
Amedisys, Inc.	CorVel Corporation	LHC Group, Inc.	The Ensign Group, Inc.
Apollo Medical Holdings, Inc.	Encompass Health Corporation	National HealthCare Corporation	Veradigm Inc. (formerly Allscripts)

In addition to comparative market data (peer group and survey data), the Compensation Committee takes into consideration other factors, including global economic conditions and an individual’s role, tenure, experience, skills and performance when making compensation decisions.

2023 Executive Compensation Program Decisions

The following decisions were made for fiscal year 2023 regarding each of these compensation components:

Base Salary

The Compensation Committee has periodically reviewed and set salaries for NEOs at levels intended to be competitive, as further discussed under the caption “—Approach for Developing the Executive Compensation Program,” and to provide the appropriate level of fixed compensation for each individual’s role at the Company. In determining the NEOs’ base salaries, the Compensation Committee has considered the internal pay comparisons within the executive group at the Company, individual performance, overall financial performance of the Company, and market data, as appropriate. Annual base salaries for our NEOs were as follows:


Name	2022 (1)	2023 (1)
L. Heath Sampson (2)	$750,000	$750,000
Barbara Gutierrez (3)	$—	$500,000
Anne Bailey (3)	$—	$500,000
Ilias Simpson	$500,000	$500,000
Henry Toledo (3)	$—	$425,000

1. Reflects annual base salaries for our NEOs established for the full calendar years ended December 31, 2023 and 2022, respectively, without adjustment for partial years worked.


Modivcare 2024 Proxy Statement			35


Executive Compensation			TABLE OF CONTENTS

2. Mr. Sampson began serving as our interim Chief Executive Officer in July 2022. The base salary in 2022 reflects his salary upon becoming the Chief Executive Officer in November 2022, which such base salary had retroactive effect to July 2022.

3. Mses. Gutierrez and Bailey and Mr. Toledo began their employment with us in 2023 and, therefore, did not have base salaries in 2022.

Short-Term Incentive Plan

In the design of the 2023 STI plan, the Compensation Committee, in consultation with management, adopted Compensation Adjusted EBITDA targets that were tied to the Company’s Board approved 2023 operating budget. As shown in the reconciliation included in Appendix A to this Proxy Statement, Compensation Adjusted EBITDA is calculated by increasing the Company’s publicly disclosed EBITDA by the amount by which certain operating expenses identified in such reconciliation were not included in the Company’s Board approved 2023 operating budget. As was the case in 2020, 2021 and 2022, the 2023 STI plan provided for a bonus opportunity for each executive based 50% on consolidated financial performance, measured in 2023 by Compensation Adjusted EBITDA, and 50% on individual performance goals established by the Compensation Committee in consultation with the CEO, with the exception of Mr. Toledo who was entitled to receive 100% of his 2023 STI target (prorated from his respective start date in August 2023) as stipulated in his offer letter dated July 18, 2023.

Compensation Adjusted EBITDA for 2023 was approximately $165 million and such amount was used to determine the STI payout at 50% of target under the 2023 STI.


Named Executive Officer	Target STI Opportunity as a % of Salary		Target STI Opportunity Value ($) (1)

L. Heath Sampson	100	%	750,000
Barbara Gutierrez	100	%	500,000
Anne Bailey	100	%	500,000
Ilias Simpson	100	%	500,000
Henry Toledo	75	%	318,750

1. The amounts listed in this column are annualized targets and do not necessarily reflect the amounts actually paid to NEOs.

With respect to the portion of the STI that was tied to individual performance, the amount of the award for each executive was calculated as (A) 50% of the Target Incentive Plan Opportunity Value set forth above, multiplied by (B) the percentage of individual performance objectives achieved, multiplied by (C) 50% (the 2023 STI payout). Mr. Sampson’s individual performance objectives centered around achievement of the Company’s Compensation Adjusted EBITDA as well as achievement of objectives determined during the time he served as CFO of the Company. For the other NEOs, performance objectives centered around, among other things:

• reducing cost overrides in our Mobility business;

• improving on-time performance in our Mobility business;

• expanding the sales pipeline;

• achieving revenue targets;

• increasing Caregiver supply in our Personal Care business;

• reducing annual real estate costs;

• implementing a leadership development program;

• building sustainable processes in governance and risk management; and

• achieving integration synergies.

As a result of their respective performance, each of Messrs. Sampson and Simpson and Mses. Gutierrez and Bailey was determined to have achieved 100% of their respective performance goals. As a result, such NEOs were awarded 50% of their total target bonuses (prorated from their respective start dates in September 2023 and March 2023, in the case of Mses. Gutierrez and Bailey, respectively), payable 100% in cash. As stipulated by Mr. Toledo’s offer letter dated July 18, 2023, Mr. Toledo was entitled to 100% of his STI target, prorated from his respective start date in August 2023.


36			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Long-Term Incentives

In an effort to retain, motivate, and continue to align the Company’s executive officers’ interests with stockholders’ interests and stockholder value creation, the Compensation Committee grants long-term incentive awards under its LTI to the executive officers as deemed appropriate by the Compensation Committee from year to year or as required by contractual arrangements, as applicable. The Compensation Committee introduced a new structure of PRSUs in 2023 which vest three years from the grant date at various payout percentages depending on the Company’s achievement of certain Adjusted EBITDA and Revenue goals set by the Company, as applicable. These PRSUs were included in the LTI grants made to executive officers in a ratio of 60% PRSUs and 40% restricted stock units, which have inherent retention value.

Mr. Sampson received an award in March 2023 related to his performance as the Chief Financial Officer that consisted of 100% PRSUs with a fair value per share equal to the closing stock price of the underlying shares of common stock on the grant date based on the probable satisfaction of achieving certain Adjusted EBITDA and Revenue goals set by the Company. Mr. Sampson received an additional award grant in August 2023 in connection with the Company’s annual 2023 LTI award that consisted of 60% PRSUs with a fair value per share equal to the closing stock price of the underlying shares of common stock on the grant date based on the probable satisfaction of achieving certain Adjusted EBITDA goals set by the Company and 40% RSUs. Mr. Simpson received an award in February 2023 as a one-time retention bonus and an award in March 2023 related to his STI award for 2022 performance, both of which consisted of 100% PRSUs with a fair value per share equal to the closing stock price of the underlying shares of common stock on the grant date based on the probable satisfaction of achieving certain Adjusted EBITDA and Revenue goals set by the Company. Mr. Simpson received an additional award grant in August 2023 in connection with the Company’s annual 2023 LTI award that consisted of 60% PRSUs with a fair value per share equal to the closing stock price of the underlying shares of common stock on the grant date based on the probable satisfaction of achieving certain Adjusted EBITDA goals set by the Company and 40% RSUs. Each of Mr. Toledo and Mses. Gutierrez and Bailey received grants in connection with their employment arrangements with the Company which were awarded in September 2023 for Mr. Toledo and Ms. Gutierrez and in May 2023 for Ms. Bailey. The Compensation Committee considered various factors in determining the value of the individual equity grants, including the individuals’ roles, performance, historical LTI grants, and market data.

The following table summarizes the equity grants made to the NEOs during 2023. For more details regarding the equity grants to our NEOs, please see the Grants of Plan Based Awards Table on page 43.



Named Executive Officer	Grant Date		Exercise Price of Stock Options ($)	Stock Options (# of underlying shares)	Restricted Stock Units	Performance Restricted Stock Units	Grant Date Fair Value ($) (1)

L. Heath Sampson	3/6/2023	(2)	—	—	—	1,022	91,949
	8/31/2023	(3)	—	—	17,757	26,635	1,424,983
Barbara Gutierrez	9/18/2023	(4)	—	—	8,573	12,860	749,941
Anne Bailey	5/16/2023	(5)	53.10	11,809	11,770	7,062	1,249,976
Ilias Simpson	2/15/2023	(6)	—	—	—	2,467	249,907
	3/16/2023	(7)	—	—	—	872	73,047
	8/31/2023	(8)	—	—	9,345	14,018	749,952
Henry Toledo	9/5/2023	(9)	—	—	17,287	13,094	887,429

1. This column shows the aggregate grant date fair value of the stock options, restricted stock units and performance restricted stock units calculated in accordance with FASB ASC Topic 718, based on the assumptions set forth in our 2023 Annual Report on Form 10-K for the year ended December 31, 2023 (Note 13, Stock-Based Compensation and Similar Arrangements). The grant date fair value of the performance restricted stock units is calculated using the closing stock price on the date of the grant, as determined under FASB ASC 718 for awards with a performance condition, based on the probable outcome of the performance condition as of the grant date.

2. Granted as part of Mr. Sampson’s STI award for 2022 performance. The PRSUs vest on March 6, 2026, subject to the satisfaction of the performance conditions and subject to continued employment through such date.

3. This grant represents the annual 2023 LTI award. The RSUs vest in approximately 1/3 increments on August 31, 2024, August 31, 2025 and August 31, 2026, and the PRSUs vest on August 31, 2026, subject to the satisfaction of the performance conditions, and in each case, subject to continued employment through such dates.


Modivcare 2024 Proxy Statement			37


Executive Compensation			TABLE OF CONTENTS

4. Granted in connection with Ms. Gutierrez’s appointment as Chief Financial Officer. The RSUs vest in approximately 1/3 increments on September 18, 2024, September 18, 2025, and September 18, 2026, and the PRSUs vest on September 18, 2026, subject to the satisfaction of the performance conditions, and, in each case subject to continued employment through such dates.

5. Granted in connection with Ms. Bailey’s appointment as President of ModivCare Home. The stock options and RSUs vest in approximately 1/3 increments on May 16, 2024, May 16, 2025 and May 16, 2026, and the PRSUs vest on May 16, 2026, subject to the satisfaction of the performance conditions, and in each case, subject to continued employment through such dates.

6. Granted as a one-time retention bonus for Mr. Simpson. The PRSUs were scheduled to vest on February 15, 2026, subject to the satisfaction of the performance conditions, however, due to the termination of Mr. Simpson’s employment as of May 1, 2024, his unvested PRSUs as of such date will be forfeited and will not vest.

7. Granted as part of Mr. Simpson’s STI award for 2022 performance. The PRSUs were scheduled to vest on March 16, 2026, subject to the satisfaction of the performance conditions, however, due to the termination of Mr. Simpson’s employment as of May 1, 2024, his unvested PRSUs as of such date will be forfeited and will not vest.

8. This grant represents the annual 2023 LTI award. The RSUs were scheduled to vest in approximately 1/3 increments on August 31, 2024, August 31, 2025 and August 31, 2026, and the PRSUs were scheduled to vest on August 31, 2026, subject to the satisfaction of the performance conditions, however, due to the termination of Mr. Simpson’s employment as of May 1, 2024, his unvested RSUs and PRSUs as of such date will be forfeited and will not vest.

9. Granted in connection with Mr. Toledo’s appointment as Chief People Officer. The RSUs vest in approximately 1/3 increments on September 5, 2024, September 5, 2025, and September 5, 2026, and the PRSUs vest on September 5, 2026, subject to the satisfaction of the performance conditions, and, in each case subject to continued employment through such dates.

Benefits and Perquisites

401(k) Plans

All NEOs are eligible to participate in our 401(k) Plan and to receive a Company match, subject to plan requirements and contribution limits established under the Internal Revenue Code of 1986, as amended (the “IRC”). NEOs are eligible to receive matching contributions under our 401(k) Plan up to 6% of the amount of the participant’s elective contributions.

Executive Non-Qualified Deferred Compensation Plan

Our NEOs are eligible to participate in our Executive Deferred Compensation Plan (the “Deferred Compensation Plan”), pursuant to which participants may elect to defer up to 10% of their annual base salary and up to 100% of their annual cash bonus. Amounts deferred under the Deferred Compensation Plan, as adjusted for applicable earnings gains and losses and fees, are credited to an account in the participant’s name and remain fully vested at all times. Participants may allocate account balances to one or more notional investments, and the value of their Deferred Compensation Plan account balance may increase or decrease based on the performance of their selected investment options.

Under the Deferred Compensation Plan, participants may elect to receive distributions of their deferred amounts either upon separation from service or as of a specified in-service distribution date. Upon separation from service for any reason, the deferred amounts will be paid in a lump sum within eight months following the separation date. In addition, participants may elect to receive a hardship distribution of deferred amounts due to an eligible unforeseeable emergency.

During fiscal year 2023, none of our NEOs elected to participate in the Deferred Compensation Plan.

Other Benefits and Perquisites

During fiscal year 2023, our NEOs received, to varying degrees, a limited amount of other benefits, including certain group life, health, medical and other non-cash benefits generally available to all salaried employees. More detail on these benefits and perquisites may be found in the “Summary Compensation Table.”


38			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Other Compensation Policies

Stock Ownership Guidelines for NEOs

We believe that promoting stock ownership aligns the interests of our continuing NEOs with those of our stockholders and provides strong motivation to build stockholder value. Under our stock ownership guidelines, continuing NEOs are expected to own shares of our Common Stock with a value equal to the following multiple of their respective base salaries:


Executive			Stock Ownership Guideline as a Multiple of Salary
CEO			5x annual base salary
Other NEOs			3x annual base salary

The following will count towards meeting the required holding level:

• shares held directly or indirectly;

• shares underlying any vested RSUs received under our equity-based compensation program;

• shares underlying any unvested time-based restricted shares or RSUs received under our equity-based compensation program (calculated on an assumed net after-tax basis);

• shares owned jointly with, or in trust for, immediate family members residing in the same household.

Continuing NEOs are required to hold all compensatory shares of our Common Stock until they have reached the required holding level described above. This holding requirement does not apply to shares purchased by an NEO in the market or from the Company for cash unless acquired by exercise of a compensatory option. In the event an NEO does not achieve his or her holding level set forth above and sells shares of our Common Stock in violation of the Company’s stock ownership guidelines, the Board will consider all relevant facts and take such actions as it deems appropriate under the circumstances. Given that Mr. Sampson joined the Company in 2021, Mr. Simpson joined the Company in 2022, and Mses. Gutierrez and Bailey and Mr. Toledo joined the Company in 2023, none of the NEOs met the required holding level guidelines at December 31, 2023.

Clawback

It is the Company’s policy that the Compensation Committee has, to the extent permitted by governing law, the sole and absolute authority to make retroactive adjustments to any excess cash or equity-based incentive compensation paid to executive officers and certain other officers where the payment was predicated upon the achievement of certain financial results that were subsequently the subject of a restatement. In accordance with the Company’s clawback policy (the “Clawback Policy”), which is intended to comply with Nasdaq rules implementing Exchange Act Rule 10D-1, any such incentive compensation received within the three fiscal years prior to the restatement is subject to retroactive adjustment. The Company may seek cash repayment from the executive, offset compensation due to the executive by the amount subject to retroactive adjustment or cancel the executive’s outstanding awards. Where applicable, we will seek to recover any amount determined to have been inappropriately received by the individual executive.

In addition to the Clawback Policy, the 2006 Plan grants the Compensation Committee the sole and absolute discretion to impose any further clawback, recovery or recoupment provisions in equity award agreements as the Compensation Committee determines necessary, advisable or appropriate, including the recoupment of previously acquired equity awards or other cash or property upon the occurrence of a termination for cause or a violation of post-employment restrictive covenants.

Anti-hedging / anti-pledging

We have a policy that prohibits employees, executive officers and the Board from engaging in any hedging or monetization transactions, or other financial arrangements that establish a short position in our Common Stock or otherwise are designed to hedge or offset a decrease in market value. In addition, we have a policy that prohibits our employees, executive officers and the Board from pledging our Common Stock as collateral for a loan or for a margin account.

Change in Control, Severance Arrangements and Severance Payments

During fiscal year 2023, we had employment offer letters with each of our NEOs. The employment letters with Messrs. Sampson, Simpson, and Toledo and Mses. Gutierrez and Bailey provide for a severance payment upon the termination of employment under specified circumstances, including termination upon or following a change in control as described below under “— Offer Letter Agreements with the Named Executive Officers” and “—Potential Payments Upon Termination or Change in Control.”


Modivcare 2024 Proxy Statement			39


Executive Compensation			TABLE OF CONTENTS

Impact of Tax Treatment on Compensation

The Compensation Committee endeavors to structure compensation so that we may take a tax deduction, but it does not have a policy requiring that all compensation must be deductible and it may, from time to time, authorize compensation that is not tax deductible, including where it deems appropriate or necessary in order to ensure competitive levels of total compensation for our NEOs and where doing so would be in the best interests of the Company. For taxable years beginning after 2017, Section 162(m) of the IRC generally disallows tax deductions for annual compensation in excess of $1.0 million paid to our NEOs.

Other provisions of the IRC can also affect compensation decisions. Section 409A of the IRC, which governs the form and timing of payment of deferred compensation, imposes sanctions, including a 20% additional tax and an interest penalty, on a recipient of deferred compensation that does not comply with Section 409A. The Compensation Committee takes into account the potential implications of Section 409A in determining the form and timing of compensation awarded to our executives and strives to structure its compensation plans to meet these requirements.

Section 280G of the IRC disallows a company’s tax deduction for payments received by certain individuals in connection with a change in control to the extent that the payments exceed an amount approximately three times their average annual compensation (an “excess parachute payment”) and Section 4999 of the IRC imposes a 20% excise tax on those payments. The Compensation Committee also takes the provisions of Sections 280G and 4999 into account in structuring compensation, endeavoring to enable the Company to take a tax deduction and executives to avoid the excise tax.

Compensation Committee Report

The Compensation Committee operates under a written charter and is comprised entirely of directors meeting the independence requirements of NASDAQ listing rules. The Board established this committee to discharge the Board’s responsibilities relating to compensation of our CEO and each of our other executive officers. The Compensation Committee has overall responsibility for decisions relating to all compensation plans, policies, and benefit programs as they affect the CEO and other executive officers.

The Compensation Committee has reviewed and discussed with ModivCare’s management the preceding section entitled “Compensation Discussion and Analysis.” Based on this review and discussions with management, the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in the 2023 Annual Report through filing of this Proxy Statement.

Compensation Committee

• Richard A. Kerley (Chairperson)

• Todd J. Carter

The information contained above in this section titled “Compensation Committee Report” will not be considered “soliciting material” or to be “filed” with the SEC, nor will that information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference into a filing.


40			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Summary Compensation Table

The following table sets forth certain information with respect to compensation paid by us for services rendered in all capacities to us and our subsidiaries during the fiscal years ended December 31, 2023, 2022 and 2021 to our NEOs, which group is composed of (1) each person who served as our CEO during fiscal year 2023, (2) each person who served as our CFO during fiscal year 2023, (3) each of our three other most highly compensated executive officers who were employed by us on December 31, 2023:



Name	Year	Salary ($)	Bonus ($) (1)	Stock Awards ($) (2)	Option Awards ($) (3)	Non-Equity Incentive Plan Compensation ($) (4)	All Other Compensation ($) (5)		Total ($)

L. Heath Sampson (6) President, Chief Executive Officer, and Former Chief Financial Officer	2023	758,654	—	1,516,933	—	379,327	37,848		2,692,762
	2022	602,481	—	1,069,368	291,573	271,116	32,247		2,266,785
	2021	400,822	—	356,306	356,265	360,740	33,313		1,507,446
Barbara Gutierrez (7) Chief Financial Officer	2023	134,615	—	749,941	—	67,308	2,248		954,112
Anne Bailey (8) President of Home	2023	384,615	—	999,979	249,997	192,308	7,767		1,834,666
Ilias Simpson (9) Former President of Mobility	2023	505,769	—	1,072,907	—	252,885	25,670		1,857,231
	2022	365,385	—	474,621	125,000	319,231	174,657	(10)	1,458,894
Henry Toledo (11) Chief People Officer	2023	138,942	256,250	887,429	—	—	1,409		1,284,030

1. With respect to Mr. Toledo, this includes a one-time cash sign-on bonus of $150,000, and a prorated annual incentive bonus of $106,250, each as provided in his offer letter.

2. The compensation included in this column represents the aggregate grant date fair value of the equity awards granted during the year indicated, calculated in accordance with FASB ASC Topic 718, based on the assumptions set forth in our 2023 Annual Report on Form 10-K for the year ended December 31, 2023 (Note 13, Stock-Based Compensation and Similar Arrangements). With respect to Messrs. Sampson and Simpson, a portion of their 2022 annual incentive bonuses were paid in the form of PRSUs in March 2023, which such awards are included in the total value of stock awards granted in 2023. Stock awards are a combination of time-based restricted stock units and performance-based restricted stock units. The grant date fair value of the PRSUs is calculated using the closing stock price on the date of the grant, as determined under FASB ASC 718 for awards with a performance condition, based on the probable outcome of the performance condition as of the grant date. The amounts do not necessarily reflect the actual value received by the executive, which may be more or less than the amount shown or zero. Assuming the maximum level of performance were achieved, the grant date fair value of the PRSUs granted during fiscal year 2023 to each NEO would equal the following:



Name			Value of PRSUs Assuming Maximum Performance ($)

L. Heath Sampson			1,893,866
Barbara Gutierrez			899,943
Anne Bailey			749,984
Ilias Simpson			1,545,865
Henry Toledo			764,951

3. This column shows the aggregate grant date fair value of the stock option awards granted. The grant date fair values have been calculated in accordance with FASB ASC Topic 718, based on the assumptions set forth in our 2023 Annual Report on Form 10-K for the year ended December 31, 2023 (Note 13, Stock-Based Compensation and Similar Arrangements). With respect to Ms. Bailey, the options listed in this column were granted pursuant to the terms of her offer letter.


Modivcare 2024 Proxy Statement			41


Executive Compensation			TABLE OF CONTENTS

4. Includes annual incentive bonuses earned for the year indicated, but paid in March of the following year. With respect to Messrs. Sampson and Simpson, a portion of their 2022 annual incentive bonuses were paid in the form of PRSUs in March 2023, which such awards are included in the total value of stock awards granted in 2023. With respect to Mses. Gutierrez and Bailey, their annual incentive bonuses were prorated from their respective employment dates.

5. We provide the NEOs with certain group life, health, medical and other non-cash benefits generally available to all salaried employees, which are included in this column. For fiscal year 2023, the amounts in this column include, among other things, the following:



Name	Health, Dental, Life and Disability Insurance Premiums ($)	Matching Contributions under Retirement Savings Plans ($)

L. Heath Sampson	18,048	19,800
Barbara Gutierrez	2,248	—
Anne Bailey	7,767	—
Ilias Simpson	5,870	19,800
Henry Toledo	1,409	—

6. Mr. Sampson has served as President and Chief Executive Officer since July 27, 2022 and as Chief Financial Officer from February 26, 2021 to September 5, 2023.

7. Ms. Gutierrez has served as Chief Financial Officer since September 5, 2023.

8. Ms. Bailey has served as President of ModivCare Home since March 20, 2023.

9. Mr. Simpson served as President of ModivCare Mobility from April 12, 2022 until April 1, 2024. He is continuing in a transitional role with the Company until May 1, 2024.

10. In addition to certain group life, health, medical and other non-cash benefits generally available to all salaried employees disclosed above under footnote 5, the total for Mr. Simpson in this column also includes relocation expenses of $157,001 for 2022.

11. Mr. Toledo has served as Chief People Officer since August 28, 2023.


42			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Grants of Plan Based Awards Table

The following Grants of Plan Based Awards Table provides additional information about stock and option awards and non-equity incentive plan awards granted to the NEOs during the fiscal year ended December 31, 2023. The compensation plans under which the grants in the following table were made are described under “2023 Executive Compensation Program Decisions—Annual Incentive Program” and “2023 Executive Compensation Program Decisions—Long-Term Incentives” in the “Compensation Discussion and Analysis” section.


			Estimated Possible Payouts Under Non-Equity Incentive Plan Awards (1)			Estimated Possible Payouts Under Equity Incentive Plan Awards			All Other Stock Awards Number of Shares of Stock or Units (#)	All Other Option Awards; Number of Securities Underlying Options (#)	Exercise or Base Price of Option Awards ($/Sh)	Grant Date Fair Value of Stock and Option Awards ($) (5)


Name	Award	Grant Date	Threshold ($)	Target ($)	Maximum ($)	Threshold (#) (2)	Target (#) (3)	Maximum (#) (4)

L. Heath Sampson	STI	N/A	375,000	750,000	1,500,000	—	—	—	—	—	—	—
	PRSU	3/6/2023	—	—	—	511	1,022	2,044	—	—	—	91,949
	RSU	8/31/2023	—	—	—	—	—	—	17,757	—	—	570,000
	PRSU	8/31/2023	—	—	—	13,318	26,635	53,270	—	—	—	854,984
Barbara Gutierrez	STI	N/A	67,308	134,615	269,230	—	—	—	—	—	—	—
	RSU	9/18/2023	—	—	—	—	—	—	8,573	—	—	299,969
	PRSU	9/18/2023	—	—	—	6,430	12,860	25,720	—	—	—	449,971
Anne Bailey	STI	N/A	192,308	384,615	769,230	—	—	—	—	—	—	—
	RSU	5/16/2023	—	—	—	—	—	—	11,770	—	—	624,987
	Option	5/16/2023	—	—	—	—	—	—	—	11,809	53.10	249,997
	PRSU	5/16/2023	—	—	—	3,531	7,062	14,124	—	—	—	374,992
Ilias Simpson	STI	N/A	250,000	500,000	1,000,000	—	—	—	—	—	—	—
	PRSU	2/15/2023	—	—	—	1,234	2,467	4,934	—	—	—	249,907
	PRSU	3/16/2023	—	—	—	436	872	1,744	—	—	—	73,047
	RSU	8/31/2023	—	—	—	—	—	—	9,345	—	—	299,975
	PRSU	8/31/2023	—	—	—	7,009	14,018	28,036	—	—	—	449,978

Henry Toledo (6)	RSU	9/5/2023	—	—	—	—	—	—	17,287	—	—	504,953
	PRSU	9/5/2023	—	—	—	6,547	13,094	26,188	—	—	—	382,476

1. Amounts represent the threshold, target and maximum bonus opportunities under the STI for fiscal year 2023 or similar provisions of the NEOs’ employment agreement or offer letters. With respect to Mses. Gutierrez and Bailey, amounts presented are prorated to their respective employment start dates.

2. Amounts represent the number of shares of common stock to be received upon the threshold payout of 50% of target on the performance restricted stock units granted.

3. Amounts represent the number of shares of common stock to be received upon the target payout of 100% of target on the performance restricted stock units granted.

4. Amounts represent the number of shares of common stock to be received upon the maximum payout of 200% of target on the performance restricted stock units granted.


Modivcare 2024 Proxy Statement			43


Executive Compensation			TABLE OF CONTENTS

5. The amounts included in this column represent the grant date fair value of each equity award granted during the year indicated, calculated in accordance with FASB ASC Topic 718, based on the assumptions set forth in our 2023 Annual Report on Form 10-K for the year ended December 31, 2023 (Note 13, Stock-Based Compensation and Similar Arrangements). The grant date fair value of the PRSUs is calculated using the closing stock price on the date of the grant, as determined under FASB ASC 718 for awards with a performance condition, based on the probable outcome of the performance condition as of the grant date. The amounts do not necessarily reflect the actual value that has been, or will be, received by the executive, which may be more or less than the amount shown or zero.

6. Pursuant to the terms of Mr. Toledo’s offer letter, Mr. Toledo was entitled to receive 100% of his target annual incentive bonus, prorated from his August 2023 start date and therefore did not receive an STI award subject to performance-based threshold, target and maximum payout opportunities.

OFFER LETTER AGREEMENTS WITH THE NAMED EXECUTIVE OFFICERS

The following discussion and the discussion below under “—Potential Payments Upon Termination or a Change in Control” describe terms of the offer letter agreements between the Company and the NEOs. In addition to the particular provisions discussed below for each of the NEOs separately, the NEOs generally are also entitled to participate, while employed, in all employee fringe benefits generally available to the Company’s senior executives, including with respect to severance pay of up to twelve (12) months of base compensation in effect at the time of an employment termination without cause or resignation for good reason (as such terms are defined in the executive severance policy or respective agreements, as applicable), in each case subject to the applicable NEO’s execution of a release of claims in favor of the Company. Each of the NEOs also entered into a restrictive covenants agreement that contains one-year post-employment non-competition and non-solicitation covenants, as well as non-disclosure and non-disparagement covenants. Additional information with respect to potential severance payments for the NEOs is set forth below under the caption “—Potential Payments Upon Termination or a Change in Control.”

L. Heath Sampson

On November 1, 2022, L. Heath Sampson was appointed to serve as our President and Chief Executive Officer following his interim term as our interim Chief Executive Officer that began on July 27, 2022. Mr. Sampson also continued to serve as our Chief Financial Officer until September 5, 2023 when Barbara Gutierrez began her service as Chief Financial Officer. In connection with Mr. Sampson’s prior appointment as Chief Financial Officer, effective February 26, 2021, we entered into an employment letter with Mr. Sampson. Under the terms of Mr. Sampson’s employment letter dated February 24, 2021, he had an initial base salary of $475,000 and was eligible to receive a prorated short-term incentive bonus for 2021 at a target of 90% of his base salary based on performance targets set by the Compensation Committee of the Board of Directors. Mr. Sampson was granted a long-term incentive equity grant on February 26, 2021 with a target grant date value equal to 150% of his base salary, composed of 50% RSUs and 50% stock options. In connection with his appointment as President and Chief Executive Officer, on November 21, 2022, the Compensation Committee approved an increase in Mr. Sampson’s base salary to $750,000, with retroactive effect from July 27, 2022, and his short-term incentive and long-term incentive plan targets for fiscal year 2022 and 2023 remained at the 100% and 190% levels, respectively, previously set by the Compensation Committee in February 2022.

Barbara Gutierrez

Effective September 5, 2023, Barbara Gutierrez was appointed to serve as Chief Financial Officer. Under the terms of Ms. Gutierrez’s offer letter dated July 31, 2023, she had an initial base salary of $500,000 and was eligible to receive a prorated short-term incentive bonus for 2023 at a target of 100% of her base salary based on performance targets set by the Compensation Committee of the Board of Directors. Pursuant to the terms of her offer letter, Ms. Gutierrez was granted a long-term incentive equity grant on September 18, 2023 with a target grant date value equal to 150% of her base salary, composed of 60% PRSUs and 40% RSUs.

Anne Bailey

Effective March 20, 2023, Anne Bailey was appointed to serve as President of ModivCare Home. Under the terms of Ms. Bailey’s offer letter dated March 15, 2023, she had an initial base salary of $500,000 and was eligible to receive a prorated short-term incentive bonus for 2023 at a target of 100% of her base salary based on performance targets set by the Compensation Committee of the Board of Directors. Pursuant to the terms of her offer letter, Ms. Bailey was granted a long-term incentive equity grant on May 16, 2023 with a target grant date value equal to 150% of her base salary, composed of 50% PRSUs and 50% RSUs. Ms. Bailey also received an initial sign-on bonus in the form of a one-time equity grant on May 16, 2023 with a target grant date value equal to 100% of her base salary, composed of 50% stock options and 50% RSUs, in accordance with her offer letter.


44			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Ilias Simpson

Ilias Simpson’s employment letter dated April 11, 2022, terminated as of April 1, 2024 when his employment as President of ModivCare Mobility ended, although Mr. Simpson’s employment with the Company has continued in a transitional role until May 1, 2024. Under the terms of Mr. Simpson’s employment letter, he had an initial base salary of $500,000 and was eligible to receive a short-term incentive bonus for 2022 at an initial target of 80% of his base-salary, based on performance targets set by the Compensation Committee of the Board of Directors. Mr. Simpson was also eligible for an initial performance bonus of $100,000, based on the achievement of certain performance goals set by our former Chief Executive Officer in collaboration with Mr. Simpson, payable either in cash or equity, at the option of Mr. Simpson. In addition, Mr. Simpson was granted a long-term incentive equity grant on April 11, 2022 with a target grant date value equal to 100% of his base salary, comprised of 50% PRSUs, 25% RSUs and 25% stock options. Pursuant to the terms of his employment letter, Mr. Simpson was also reimbursed $157,001 in expenses for relocating to the Denver area.

Henry Toledo

Effective August 28, 2023, Henry Toledo was appointed to serve as Chief People Officer. Under the terms of Mr. Toledo’s offer letter dated July 18, 2023, he had an initial base salary of $425,000 and was entitled to receive a prorated short-term incentive bonus for 2023 at a target of 75% of his base salary, as stipulated in his offer letter. Pursuant to the terms of his offer letter, Mr. Toledo was granted a long-term incentive equity grant on September 5, 2023 with a target grant date value equal to 150% of his base salary, composed of 60% PRSUs and 40% RSUs. Mr. Toledo also received an initial sign-on bonus in accordance with his offer letter, comprised of a one-time cash payment of $150,000 and a one-time equity grant on September 5, 2023 with a target grant date value equal to $250,000, composed of 100% RSUs.


Modivcare 2024 Proxy Statement			45


Executive Compensation			TABLE OF CONTENTS

OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 2023

The following table reflects the equity awards granted by us to the NEOs outstanding at December 31, 2023:



	Option Awards				Stock Awards


Name and Grant Date	Number of Securities Underlying Unexercised Options (#) Exercisable (1)	Number of Securities Underlying Unexercised Options (#) Unexercisable (2)	Option Exercise Price ($)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#) (3)	Market Value of Shares or Units of Stock That Have Not Vested ($) (4)	Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights that have not Vested (#) (5)	Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights that have not Vested ($) (6)

L. Heath Sampson
2/26/2021	6,245	3,123	128.26	2/26/2026	926	40,735	—	—
2/8/2022	2,244	4,489	110.07	2/8/2027	1,467	64,533	2,201	96,822
11/21/2022	526	1,053	85.99	11/21/2027	382	16,804	574	25,250
3/6/2023	—	—	—	N/A	—	—	511	22,479
8/31/2023	—	—	—	N/A	17,757	781,130	13,318	585,859
Barbara Gutierrez
9/18/2023	—	—	—	N/A	8,573	377,126	6,430	282,856
Anne Bailey
5/16/2023	—	11,809	53.10	5/16/2028	11,770	517,762	3,531	155,329
Ilias Simpson
4/11/2022	1,087	2,175	109.70	4/11/2027	759	33,388	1,139	50,105
2/15/2023	—	—	—	N/A	—	—	1,234	54,284
3/16/2023	—	—	—	N/A	—	—	436	19,180
8/31/2023	—	—	—	N/A	9,345	411,087	7,009	308,326
Henry Toledo
9/5/2023	—	—	—	N/A	17,287	760,455	6,547	288,003

1. The options listed in this table have an exercise price equal to the closing market price of our Common Stock on the grant date.

2. The options granted to each of Messrs. Sampson and Simpson and Ms. Bailey during fiscal periods 2021, 2022 and 2023, as applicable, vest in three approximately equal installments on each of the first, second, and third anniversary of the grant date, in each case, subject to the executive’s continued employment. Due to the termination of Mr. Simpson’s employment as of May 1, 2024, his unvested options as of such date will be forfeited and will not vest.

3. The RSUs granted to each of Messrs. Sampson, Simpson and Toledo and Mses. Gutierrez and Bailey during fiscal periods 2021, 2022, and 2023, as applicable, vest in three approximately equal installments on each of the first, second, and third anniversary of the grant date, in each case, subject to the executive’s continued employment. Due to the termination of Mr. Simpson’s employment as of May 1, 2024, his unvested RSUs as of such date will be forfeited and will not vest.

4. The market value of the unvested RSUs was calculated using a value of $43.99 per share of Common Stock, which was the closing market price of our Common Stock on December 29, 2023.

5. Amounts represent the threshold payout of 50% of target on the performance restricted stock units granted. The PRSUs granted to each of Messrs. Sampson, Simpson and Toledo and Mses. Gutierrez and Bailey during fiscal periods 2022 and 2023, as applicable, vest on the third anniversary of the grant date, subject to the executive’s continued employment and the satisfaction of the performance objectives contained in such PRSUs. Due to the termination of Mr. Simpson’s employment as of May 1, 2024, his unvested PRSUs as of such date will be forfeited and will not vest.

6. The market value of the unvested PRSUs is based on the threshold payout of 50% and was calculated using a value of $43.99 per share of Common Stock, which was the closing market price of our Common Stock on December 29, 2023.


46			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Option Exercises and Stock Vested Table

The following table provides additional information about the value realized by the NEOs on option award exercises and stock award vesting during the year ended December 31, 2023.


	Option Awards		Stock Awards
Name	Number of Shares Acquired on Exercise (#)	Value Realized on Exercise ($)	Number of Shares Acquired on Vesting (#) (1)	Value Realized on Vesting ($) (2)
L. Heath Sampson	—	—	1,850	179,578
Barbara Gutierrez	—	—	—	—
Anne Bailey	—	—	—	—
Ilias Simpson	—	—	380	32,585
Henry Toledo	—	—	—	—

1. The amounts in this column reflect the full number of shares that vested and does not take into account shares withheld to satisfy tax obligations upon vesting.

2. Value realized on vesting is determined by multiplying the number of shares underlying the stock award by the closing stock price on the date of vesting, as reported by Nasdaq.

Non-qualified Deferred Compensation

As discussed above, although all of our NEOs are eligible to participate in our Deferred Compensation Plan, none of our NEOs participated in or had account balances in non-qualified defined contribution plans or other non-qualified deferred compensation plans maintained by us during fiscal year 2023.


Modivcare 2024 Proxy Statement			47


Executive Compensation			TABLE OF CONTENTS

Pay Versus Performance

The following disclosure illustrates the relationship between the compensation actually paid to our executive officers and the performance of the Company. The table below presents information for each of the last four fiscal years regarding (i) the total compensation for our principal executive officers serving in that capacity during the applicable fiscal year (each, a “PEO”) and the average total compensation of our other NEOs (excluding the PEO(s)) who were serving in that capacity during the applicable fiscal year as disclosed in the Summary Compensation Table (“SCT”), (ii) total compensation actually paid (“CAP”) to each PEO and the CAP to the other NEOs on average, (iii) total shareholder return (“TSR”) for the Company and its peer group, (iv) the Company’s net income (loss), and (v) the Company’s Compensation Adjusted EBITDA, which is the most important financial measure used by the Company in determining executive compensation.



Year	SCT Total		CAP (2)		Average SCT Total for non PEO NEOs ($)	Average CAP (2) to non PEO NEOs ($)	Value of Initial Fixed $100 Investment Based On:		Net Income (Loss) ($)	Adjusted EBITDA ($) (3)	Comp. Adjusted EBITDA ($) (3)


	Prior PEO ($) (1)	Current PEO ($) (1)	Prior PEO ($) (1)	Current PEO ($) (1)			TSR ($)	Peer Group TSR (S&P Health Care Services Select Industry Index) ($)

2023 (4)	N/A	2,692,762	N/A	2,248,512	1,482,510	1,529,281	74.33	124.34	( 204,460,000 )	204,439,000	164,583,000
2022 (5)	5,373,333	2,266,785	( 9,416,369 )	1,256,475	1,475,719	955,828	151.62	118.22	( 31,806,000 )	221,902,000	192,969,000
2021 (6)	3,637,550	N/A	4,708,503	N/A	1,092,956	802,089	250.57	147.19	( 6,585,000 )	205,008,000	205,008,000
2020 (7)	4,691,139	N/A	16,436,594	N/A	925,246	2,192,785	234.25	133.81	88,836,000	189,190,000	189,190,000

1. For fiscal year 2022, Daniel Greenleaf served as our CEO until his employment ended in July 2022. From July 27, 2022, L. Heath Sampson , our then-CFO, served as our CEO for the remainder of the fiscal year and for all of fiscal year 2023. Mr. Greenleaf is identified in the table as the “Prior PEO” and Mr. Sampson is identified as the “Current PEO.” Amounts earned by Mr. Sampson in fiscal year 2021 in his role as CFO are included in the NEO averages for 2021.

2. To calculate compensation actually paid, adjustments were made to the amounts reported in the Summary Compensation Table for the applicable year. A reconciliation of the adjustments for each of the PEOs and for the average of the non-PEO NEOs is set forth following the footnotes to this table.

3. Compensation Adjusted EBITDA is the metric used by the Compensation Committee to determine the STI payouts and is calculated by increasing the Company’s publicly disclosed EBITDA by impacts from the impairment of goodwill recorded, settlement related costs from executive departure and transaction and integration costs from an investment in innovation, all occurring during 2023. For 2022, Compensation Adjusted EBITDA was calculated by reducing the Company’s publicly disclosed Adjusted EBITDA by the amount by which the operating expenses identified in such reconciliation exceeded the Company’s Board approved 2022 operating budget. For 2021 and 2020, it was determined that no adjustments were required and the Compensation Committee determined the STI payouts using the Adjusted EBITDA value for such years. Compensation Adjusted EBITDA and Adjusted EBITDA are financial measures that are not presented in accordance with GAAP. A reconciliation of Compensation Adjusted EBITDA and Adjusted EBITDA are provided in Appendix A to this Proxy Statement.

4. For fiscal year 2023, our named executive officers, excluding the PEO, included (i) Barbara Gutierrez, our Chief Financial Officer, (ii) Anne Bailey, our President of ModivCare Home, (iii) Ilias Simpson, who served as our President of ModivCare Mobility, and (iv) Henry Toledo, our Chief People Officer.

5. For fiscal year 2022, our named executive officers, excluding the PEOs, included (i) Ilias Simpson, who served as our President of ModivCare Mobility, (ii) Jason Anderson, our former President of ModivCare Home (iii) Brett Hickman, our former Chief Commercial Officer, and (iv) Grover N. Wray, our former Chief Human Resources Officer.

6. For fiscal year 2021, our named executive officers, excluding the PEO, included (i) L. Heath Sampson, who served as our Chief Financial Officer, (ii) Walt Meffert, who served as our Chief Information Officer, (iii) Grover N. Wray, who served as our Chief Human Resources Officer, (iv) Kevin M. Dotts, our former Chief Financial Officer, and (v) Kenneth W. Wilson, our former Chief Operating Officer.

7. For fiscal year 2020, our named executive officers, excluding the PEO, included (i) John McMahon, who served as our Chief Accounting Officer, (ii) Kathryn Stalmack, who served as our Senior Vice President, General Counsel and Corporate Secretary, (iii) Kenneth W. Wilson, who served as our Chief Operating Officer, (iv) Kevin M. Dotts, who served as our Chief Financial Officer, and (v) Suzanne G. Smith, our former Chief Accounting Officer.


48			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Reconciliation of Compensation Actually Paid Adjustments

The following reflects adjustments made to total compensation in the Summary Compensation Table (“SCT”), reported in columns (b) and (d) in the table above, to calculate CAP, reported in columns (c) and (e) in the table above, for each fiscal year:


	Prior PEO (1)			Current PEO (1)		Average non-PEO NEOs (2)
	2020 ($)	2021 ($)	2022 ($)	2022 ($)	2023 ($)	2020 ($)	2021 ($)	2022 ($)	2023 ($)
Summary Compensation Total	4,691,139	3,637,550	5,373,333	2,266,785	2,692,762	925,246	1,092,956	1,475,719	1,482,510
(-) Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year (3)	( 1,699,645 )	( 1,699,947 )	( 4,762,378 )	( 1,360,941 )	( 1,516,933 )	( 149,701 )	( 420,720 )	( 850,727 )	( 990,063 )
(+) Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year (4)	5,066,337	1,291,121	—	936,226	1,997,762	516,965	390,666	356,906	1,113,307
(+/-) Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years (5)	6,271,922	858,909	—	( 347,599 )	( 713,297 )	668,570	40,318	( 11,584 )	( 63,371 )
(+) Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year (6)	—	—	—	—	—	—	—	—	—
(+/-) Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year (7)	2,106,841	620,870	( 825,821 )	( 237,996 )	( 211,782 )	269,160	24,657	( 14,486 )	( 13,102 )
(-) Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year (8)	—	—	( 9,201,503 )	—	—	( 37,455 )	( 325,788 )	—	—
Compensation Actually Paid	16,436,594	4,708,503	( 9,416,369 )	1,256,475	2,248,512	2,192,785	802,089	955,828	1,529,281

1. Refer to footnote 1 of the pay versus performance table above for information regarding who served as PEO during fiscal years 2020, 2021 and, partially, 2022, and who served as PEO for the remainder of fiscal year 2022 and all of 2023.

2. Refer to footnotes 4, 5, 6 and 7 above for the NEOs included in the average for each of 2023, 2022, 2021 and 2020, respectively.

3. Represents the grant date fair value of the stock option and stock awards granted during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.

4. Represents the fair value as of the indicated fiscal year-end of the outstanding and unvested option awards and stock awards granted during such fiscal year, computed in accordance with the methodology used for financial reporting purposes.

5. Represents the change in fair value during the indicated fiscal year of each option award and stock award that was granted in a prior fiscal year and that remained outstanding and unvested as of the last day of the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes and, for awards subject to performance-based vesting conditions, based on the probable outcome of such performance-based vesting conditions as of the last day of the fiscal year.

6. Represents the fair value at vesting of the option awards and stock awards that were granted and vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.

7. Represents the change in fair value, measured from the prior fiscal year-end to the vesting date, of each option award and stock award that was granted in a prior fiscal year and which vested during the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.

8. Represents the fair value as of the last day of the prior fiscal year of the option award and stock awards that were granted in a prior fiscal year and which failed to meet the applicable vesting conditions in the indicated fiscal year, computed in accordance with the methodology used for financial reporting purposes.


Modivcare 2024 Proxy Statement			49


Executive Compensation			TABLE OF CONTENTS

Performance Measures Used to Link Company Performance and Compensation Actually Paid to the Named Executive Officers

In the Company’s assessment, the most important financial performance measures used to link compensation actually paid to our NEOs, for the most recently completed fiscal year, to the Company’s performance were:

– Compensation Adjusted EBITDA

– Adjusted EBITDA

– Revenue

Relationship Between Pay and Performance

The illustrations below provide graphical descriptions of the relationships between the following:


50			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation


Modivcare 2024 Proxy Statement			51


Executive Compensation			TABLE OF CONTENTS

Potential Payments Upon Termination or Change in Control

General

The offer letters and the Company’s executive severance policy, as applicable during 2023 to each of our NEOs, provided for severance payments in the event of termination of employment under certain circumstances, including termination following a change in control (none of which include excise tax gross-ups). The receipt of the payments and benefits to these NEOs under the offer letters and policies are generally conditioned upon their complying with non-competition, non-solicitation/non-piracy and non-disclosure provisions. By the terms of such letters and policies, the executives acknowledge that a breach of some or all of the restrictive covenants described therein will entitle us to injunctive relief restraining the commission or continuance of any such breach, in addition to any other available remedies.

In entering into these letters and adopting the policy, the Compensation Committee considered legal and tax provisions, fairness to stockholders, tenure of each executive officer and general corporate practice to select the events that will trigger payments under the letters and policies, as noted below.

In April 2024, Mr. Simpson’s employment with ModivCare as President of ModivCare Mobility terminated, but his employment is continuing in a transitional role until May 1, 2024 (the “Termination Date”). In accordance with Mr. Simpson’s Separation Agreement, Mr. Simpson’s severance includes twelve months of base salary ($500,000) and twelve months of healthcare coverage ($10,300), each payable in a lump sum payment. The unvested portion of any outstanding PRSUs, RSUs, and options will be forfeited by Mr. Simpson on the Termination Date and will not vest. With respect to the vested options held by Mr. Simpson, those options will be exercisable for 90 days following the Termination Date.

The following summaries describe payouts that would have been made under the applicable arrangements to our continuing NEOs if the termination event described had happened at the end of 2023.

Resignation by Employee for Good Reason

Each of Messrs. Sampson and Toledo and Mses. Gutierrez and Bailey is entitled to certain payments upon a resignation for Good Reason (as defined below) only if such resignation for Good Reason is in connection with or within one-year following a Change in Control, as defined and detailed below under the caption “—Termination upon or following a Change in Control.”

Termination by Company without Cause

Each of Messrs. Sampson and Toledo and Mses. Gutierrez and Bailey is entitled to certain payments upon a termination without “Cause”, which is defined in the executive severance policy or offer letter agreements to include, as applicable:

• conviction of a felony or a crime involving fraud or moral turpitude;

• theft, or embezzlement, material act of dishonesty or fraud, intentional falsification of any employment or Company records, or commission of any criminal act which impairs the executive’s ability to perform appropriate employment duties for the Company;

• intentional or reckless conduct or gross negligence materially harmful to the Company or the successor to the Company after a Change in Control, including violation of a non-competition or confidentiality agreement;

• willful failure to follow lawful instructions of the person or body to which the executive reports or material violation of the Company’s material written policies; or

• gross negligence or willful misconduct or willful and continued failure in the performance of the executive’s assigned duties.

Conduct shall not be considered “willful” unless done, or omitted to be done, not in good faith and without a reasonable belief that the conduct (or lack thereof) was in the best interests of the Company.

In the event of termination without Cause each of Messrs. Sampson and Toledo and Mses. Gutierrez and Bailey would be entitled under their applicable offer letter agreements or company policy to (i) up to twelve months’ base salary and (ii) continued healthcare coverage for six months following the date of termination.

Termination due to Death

The Company’s current benefit program includes a Company-paid life insurance policy for all named executive officers. In the event an NEO’s employment were terminated due to the NEO’s death, the NEO’s heirs, personal representatives or estate would receive the life insurance proceeds.


52			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

Termination due to Disability

The Company’s current benefit program includes a Company-paid disability insurance policy for all NEOs.

Termination or Resignation for Good Reason upon or following a Change in Control

Each of Messrs. Sampson and Toledo and Mses. Gutierrez and Bailey is entitled to certain payments upon termination without cause in connection with or within 12 months after a “Change in Control”, which is defined for these purposes as an event or events in which:

• any person (other than persons who were employees of the Company more than one year before the transaction) becomes the “beneficial owner” of 50% or more of our outstanding voting securities; or

• we consummate (i) a merger or consolidation as more specifically described in the employment agreements or severance policy, as applicable, (ii) a liquidation or (iii) the sale or disposition of all or substantially all of our assets.

Each of Messrs. Sampson and Toledo and Mses. Gutierrez and Bailey is also entitled to certain payments if they resign for Good Reason in connection with or within up to 12 months after a Change in Control, as applicable. “Good Reason” is defined for these purposes as the occurrence of the following events identified in the executive severance policy or the offer letter agreement with the executive, as applicable, that is not cured within thirty days of executive’s written notice that the occurrence constitutes Good Reason: (i) a material reduction of the executive’s base salary other than a reduction which is generally applicable to all executives of the Company, (ii) a relocation of the executive to another Company facility or location more than 50 miles from the executive’s current Company location or (iii) a material reduction in responsibilities or duties to be performed for the Company. To be deemed a resignation for Good Reason, notice must be made by the executive to the Company within 30 days of the occurrence establishing the facts supporting such termination and the resignation must occur within 120 days following the expiration of the Company’s 30-day cure period.

For each of Messrs. Sampson and Toledo and Mses Gutierrez and Bailey had a Change in Control occurred and they were either terminated without Cause or resigned for Good Reason within up to twelve months following such Change in Control, each would have been entitled under their applicable offer letter agreements or company policy to receive (i) a lump sum payment of up to twelve months’ base salary, (ii) continued healthcare coverage for six months following the date of termination, and (iii) accelerated vesting of all unvested PRSUs. In addition, had a Change in Control occurred and the executive was terminated without Cause by the Company or the successor company within twelve months following such Change in Control, each of Messrs. Sampson and Toledo and Mses. Gutierrez and Bailey would have also been entitled to accelerated vesting of RSUs and option awards.

Potential Payments upon Termination of Employment or Change in Control Table

Our NEOs are not entitled to any payments or accelerated vesting of any equity awards solely in connection with or following a Change in Control, except with respect to PRSUs granted in the first half of 2023 to certain NEOs (the “Early 2023 PRSUs”). Our NEOs are only entitled to payment or accelerated vesting of equity awards (or other benefits) if there is a termination of employment in connection with or within 12 months after a Change in Control, which is commonly referred to as a so-called “double-trigger” change in control arrangement, except with respect to the Early 2023 PRSUs.

The following table quantifies the estimated maximum amount of payments and benefits under the offer letters, the Company’s executive severance policy and agreements relating to awards granted under our 2006 Plan to which the continuing NEOs would have been entitled upon termination of employment or Change in Control as of December 31, 2023 for the various reasons listed, as defined above, but without giving effect to any reduction for excess parachute payments.


Modivcare 2024 Proxy Statement			53


Executive Compensation			TABLE OF CONTENTS



Name	Event Triggering Payment	Cash Payment(s) ($)	Value of Accelerated Vesting of Stock Awards ($) (1)		Value of Accelerated Vesting of Option Awards ($) (1)	Value of Health Insurance Payments ($) (2)	Life or Disability Insurance Proceeds ($) (3)	Total ($) (4)

L. Heath Sampson	Resignation for Good Reason (5)	375,000	1,262,529		—	18,989	—	1,656,518
	Termination without Cause (6)	750,000	—		—	18,989	—	768,989
	Death	—	—		—	—	100,000	100,000
	Disability	—	—		—	—	10,000	—
	Termination Upon Change in Control (7)	375,000	2,165,731	(8)	30,819	18,989	—	2,590,531
Barbara Gutierrez	Resignation for Good Reason (9)	500,000	565,711		—	15,290	—	1,081,001
	Termination without Cause (6)	500,000	—		—	15,290	—	515,290
	Death	—	—		—	—	100,000	100,000
	Disability	—	—		—	—	10,000	—
	Termination Upon Change in Control (7)	250,000	942,838		—	15,290	—	1,208,128
Anne Bailey	Resignation for Good Reason (5)	250,000	310,657		—	13,490	—	574,147
	Termination without Cause (6)	500,000	—		—	13,490	—	513,490
	Death	—	—		—	—	100,000	100,000
	Disability	—	—		—	—	10,000	—
	Termination Upon Change in Control (7)	250,000	828,420	(10)	170,888	13,490	—	1,262,788





Henry Toledo	Resignation for Good Reason (9)	425,000	576,005		—	16,532	—	1,017,537
	Termination without Cause (6)	425,000	—		—	16,532	—	441,532
	Death	—	—		—	—	100,000	100,000
	Disability	—	—		—	—	10,000	—
	Termination Upon Change in Control (7)	212,500	1,336,460		—	16,532	—	1,565,492

1. Calculated based on the fair value of the awards as of December 31, 2023. With respect to the PRSUs, the amount is based on the specified payout under the terms of the respective award agreements.

2. The value of healthcare coverage is based on six months of coverage following the date of termination.

3. Under our Long-Term Disability insurance, each NEO under the age of 60 who is terminated due to Disability is entitled to a monthly payment of $10,000 until he or she is 65 years old.

4. Amounts in the total column do not include the $10,000 monthly payments each NEO would receive until the age of 65 if terminated due to Disability.

5. Termination payment applicable only if the resignation for Good Reason occurs upon or within one-year following a Change in Control. Cash Payment includes six months of base salary, payable in one lump sum payment. The amounts disclosed under the “Value of Accelerated Vesting of Stock Awards” column represents the value of accelerated vesting of all PRSUs.

6. Cash Payment includes twelve months of base salary, payable in one lump sum payment.

7. Cash Payment includes six months of base salary, payable in one lump sum payment. The amounts disclosed under the “Value of Accelerated Vesting of Stock Awards” column represents the value of accelerated vesting of all RSUs and PRSUs.

8. The Early 2023 PRSUs are subject to accelerated vesting at 100% of target in the event of a Change in Control without termination. The value of accelerated vesting of such Early 2023 PRSUs is $90,855.

9. Termination payment applicable only if the resignation for Good Reason occurs upon or within one-year following a Change in Control. Cash Payment includes twelve months of base salary, payable in one lump sum payment. The amounts disclosed under the “Value of Accelerated Vesting of Stock Awards” column represents the value of accelerated vesting of all PRSUs.

10. The Early 2023 PRSUs are subject to accelerated vesting at 100% of target in the event of a Change in Control without termination. The value of accelerated vesting of such Early 2023 PRSUs is $310,657.


54			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Executive Compensation

CEO Pay Ratio Disclosure

Pay Ratio Methodology

To determine the estimated ratio of CEO pay to median employee pay (the “Pay Ratio”) in accordance with Item 402(u) of Regulation S-K of the Securities Act, we considered our entire employee population of approximately 24,000 employees who received paychecks during fiscal 2021 (excluding the CEO) and who were employed by us as of December 31, 2021, however, we did not include 7,213 employees of Care Finders or VRI, which were recently-acquired subsidiaries at such time. We used compensation paid during fiscal year 2021 to determine our median employee, and annualized pay for those employees who commenced work during fiscal year 2021. For 2023, we determined that there had been no material change in our employee population or employee compensation arrangements as compared to 2021 that would result in a significant change to our pay ratio disclosure, including the addition of previously omitted employees of Care Finders and VRI. As such, we would be permitted to use the same median employee as 2021. Due to a change in the circumstances of the individual previously identified as our median employee, however, for 2023 we substituted a median employee whose pay was substantially similar to the median employee selected for 2021, as permitted by the SEC. The Summary Compensation Table (“SCT”) total compensation, as calculated in accordance with Item 402(u)(2) of Regulation S-K of the Securities Act, of this median employee was $13,057 in fiscal year 2023. Our median employee is a caregiver working part-time with 20 hours per week or less.

The CEO pay used for purposes of calculating the Pay Ratio is $2,692,762, the SCT total compensation paid to our CEO, L. Heath Sampson, from January 1, 2023 through December 31, 2023.

As a result, the reasonable estimated ratio of CEO pay to median employee pay, calculated in a manner consistent with Item 402(u) of Regulation S-K of the Securities Act is 207:1. The SEC’s pay ratio disclosure rules permit the use of estimates, assumptions, and adjustments. We believe that the foregoing pay ratio is a reasonable estimate calculated in a manner consistent with the SEC’s pay ratio disclosure rules.

Please keep in mind that under the SEC’s rules and guidance, there are numerous ways to determine the compensation of a company’s median employee, including the employee population sampled, the elements of pay and benefits used, any assumptions made and the use of statistical sampling. In addition, no two companies have identical employee populations or compensation programs, and pay, benefits and retirement plans differ by country even within the same company. As such, our pay ratio may not be comparable to the pay ratio reported by other companies.


Modivcare 2024 Proxy Statement			55


TABLE OF CONTENTS

Proposal Two:

Advisory vote to approve named executive officer compensation

Section 14A of the Exchange Act provides stockholders an opportunity to cast a non-binding advisory vote to approve the compensation of the “named executive officers” identified in the Summary Compensation Table of this document.

The Compensation Committee has considered that the holders of approximately 99% of the votes cast at each of our 2023 and 2022 annual meetings of stockholders, respectively, approved, on an advisory basis, the compensation of our NEOs as disclosed in the Proxy Statement for those annual meetings.

As described in detail under the heading “Executive Compensation—Compensation Discussion and Analysis,” above, our executive compensation programs are designed to attract, motivate, and retain our NEOs, who are critical to our success. Under these programs, our NEOs are rewarded for the achievement of specific annual, long-term and strategic goals, corporate goals, and the realization of increased stockholder value. Please read the “Compensation Discussion and Analysis” beginning on page 30 for additional details about our executive compensation programs, including information about the fiscal year 2023 compensation of our NEOs.

We believe that the compensation programs offered to our NEOs should support the creation of stockholder value and achievement of our financial goals. Accordingly, our guiding compensation principles focus on:

• attracting, retaining, and motivating high-performing leaders;

• aligning the interests of our executives with those of our stockholders, and incentivizing stockholder value creation;

• linking a meaningful portion of executive compensation to achievement of key financial, operational, and capital allocation performance goals; and

• maintaining a significant portion of compensation based on at-risk opportunities including equity awards tied to stock price

Our Compensation Committee has a long history of performance-based pay practices and considers numerous factors when setting compensation for our NEOs including:

• actual and adjusted EBITDA, earnings per share, return on equity performance, and stockholder value created;

• goals and objectives set for each executive officer at the beginning of the year; and

• recommendations of an independent third-party executive compensation consultant

Other considerations include individual performance, internal pay comparisons within the executive group at the Company, overall financial performance of the Company, and market data.

Board Recommendation

____

The Board unanimously recommends that you vote “FOR” the compensation of our named executive officers, as disclosed in this Proxy Statement.


56			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Proposal Three

Our annual incentive cash compensation and equity-based compensation programs are designed to be performance-based and to incentivize achievement of the Company’s short- and long-term financial, operation and strategic goals. Our long-term incentive program uses equity grants to incentivize performance and reward our executives for stockholder value creation. We believe this structure encourages an ownership mentality that motivates our management to create stockholder value over a multi-year period.

Our Compensation Committee continually reviews the compensation programs for our NEOs to ensure they achieve the desired goals of aligning our executive compensation structure with our stockholders’ interests and current market practices.

We are asking our stockholders to indicate their support for our NEO compensation as described in this Proxy Statement. This proposal, commonly known as a “Say-on-Pay” proposal, gives our stockholders the opportunity to express their views on our NEOs’ compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our NEOs and the philosophy, policies and practices described in this Proxy Statement. Accordingly, we will ask our stockholders to vote “FOR” the following resolution at the Annual Meeting:

“RESOLVED, that the Company stockholders approve, on a non-binding advisory basis, the compensation of the named executive officers, as disclosed in the Company’s Proxy Statement for the 2024 Annual Meeting of Stockholders pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the 2023 Summary Compensation Table and the other related tables and disclosure.”

The Say-on-Pay vote is advisory, and therefore not binding on the Company, the Compensation Committee or the Board. The Company values the opinions of our stockholders and to the extent there is any significant vote against the NEO compensation as disclosed in this Proxy Statement, we will consider our stockholders’ concerns and the Compensation Committee will evaluate whether any actions are necessary to address those concerns. We currently conduct this vote on an annual basis, and, unless we determine subsequently to change our current practices concerning the frequency of the voting on executive compensation, we expect the next Say-on-Pay vote will occur at our 2025 annual meeting of stockholders.


ü
						The Board unanimously recommends that you vote “FOR” the compensation of our named executive officers, as disclosed in this Proxy Statement.


Modivcare 2024 Proxy Statement			57


TABLE OF CONTENTS

Proposal Three:

Ratification of Appointment of Independent Registered Public Accounting Firm

The Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023 was KPMG LLP. The Audit Committee of the Board has selected KPMG as its independent registered public accounting firm to audit the Company’s consolidated financial statements for the fiscal year ending December 31, 2024.

Although we are not required to do so, we believe that it is appropriate for us to request stockholder ratification of the appointment of KPMG as our independent registered public accounting firm. If stockholders do not ratify the appointment, though it may nevertheless retain KPMG, the Audit Committee will investigate the reasons for the stockholders’ rejection and reconsider the appointment. In addition, even if the stockholders ratify the selection of KPMG, the Audit Committee may in its discretion appoint a different independent registered public accounting firm at any time during the year if the Audit Committee determines that a change is in the best interest of the Company.

The Company has been advised that representatives of KPMG will be present at the Annual Meeting with the opportunity to make a statement if the representatives desire to do so. It is expected that the representatives will be available to respond to appropriate questions.

Board Recommendation

____

The Board unanimously recommends that you vote “FOR” the ratification of the appointment of KPMG as our independent registered public accounting firm for the fiscal year ending December 31, 2024.


ü
						The Board unanimously recommends that you vote “FOR” the ratification of the appointment of KPMG as our independent registered public accounting firm for the fiscal year ending December 31, 2024.


58			Modivcare 2024 Proxy Statement


			TABLE OF CONTENTS

Audit Committee Report

The Audit Committee of the Board consists of Mr. Kerley, Ms. Norwalk, Mr. Samant and Mr. Wright. Mr. Kerley is the Chairperson of the Audit Committee.

The Audit Committee operates under a written charter adopted by the Board, a copy of which is available on the Company’s website at www.ModivCare.com/governance.

The Audit Committee has reviewed and discussed with management its assessment and report on the effectiveness of ModivCare’s internal control over financial reporting as of December 31, 2023, which it made using the criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. The Audit Committee has also reviewed and discussed with KPMG, the Company’s independent registered public accounting firm, its audit and report on ModivCare’s internal control over financial reporting. ModivCare published these reports in its 2023 Annual Report.

With respect to the Company’s previously disclosed internal control over financial reporting material weakness remediation efforts, the Company’s management, which is being overseen and held accountable by the Audit Committee in this effort, has made significant strides in fully remediating and eliminating a number of the identified deficiencies culminating in the material weakness. As disclosed in the 2023 Annual Report, during the fiscal year ended December 31, 2023, management completed the remediation efforts necessary to remediate and eliminate fully and effectively the material weaknesses concerning the Company’s NEMT and Corporate and Other segments related to the payroll processing function and change management and logical access controls, and the Company’s PCS segment related to its reporting lines and identification of appropriate authorities and responsibilities. The Audit Committee continues to motivate management to focus on projects that automate, standardize, and centralize the Company's control environment as it continues to integrate the PCS segment and remediate and eliminate fully and effectively the remaining deficiencies in the Company’s internal control over financial reporting.

The Audit Committee has also reviewed and discussed with management and KPMG the audited consolidated financial statements of ModivCare for the fiscal year ended December 31, 2023. Management represented to the Audit Committee that ModivCare’s consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States. The Audit Committee also discussed with representatives of KPMG the matters required to be discussed by the applicable requirements of the Public Company Accounting Oversight Board (“PCAOB”).

The Audit Committee received the written disclosures and the confirming letter from KPMG required by applicable requirements of the PCAOB regarding the independent auditor’s communications with the Audit Committee concerning independence and discussed with KPMG its independence from ModivCare.

Based on these reviews and discussions and in reliance thereon, the Audit Committee recommended to the Board that the audited financial statements be included in the 2023 Annual Report.

The Audit Committee

Richard A. Kerley (Chairperson)
Leslie V. Norwalk
Rahul Samant
Frank J. Wright

The information contained above in this section titled “Audit Committee Report” will not be considered “soliciting material” or to be “filed” with the SEC, nor will that information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, except to the extent that we specifically incorporate it by reference into a filing.


Modivcare 2024 Proxy Statement			59


TABLE OF CONTENTS

Independent Registered Public Accountants

Fees of Independent Registered Public Accounting Firm

Fees for professional services provided by KPMG, the Company’s independent registered public accounting firm, for the fiscal years ended December 31, 2023 and 2022, in each of the following categories were:



	Fiscal Year Ended December 31,


	2022 ($)	2023 ($)

Audit fees	3,261,912	3,406,300
Audit related fees	275,000	—
Tax fees	246,733	37,100
All other fees	—	—
Total	3,783,645	3,443,400

Audit Fees

Audit fees consisted of amounts incurred for services performed in association with the annual financial statement audit (including required interim reviews), the audit of the Company’s internal control over financial reporting, and for services provided in connection with stand-alone or statutory audits and regulatory filings or engagements.

Audit Related Fees

Audit related fees consisted of a real time IT system assessment related to the WorkDay IT system implementation.

Tax Fees

Tax fees consisted of amounts incurred for professional services rendered by KPMG for tax compliance, transfer pricing and tax consulting.

All Other Fees

There were no other fees incurred for services rendered by KPMG during the periods presented.

Independence

The Audit Committee has considered and determined that the services provided by KPMG were compatible with KPMG maintaining their independence.

Audit Committee Pre-Approval Policies

The Audit Committee has adopted a policy that requires advance approval of all audit, audit related, tax services and other services performed by the independent auditor. The policy provides for pre-approval by the Audit Committee of specifically defined audit and non-audit services. Unless the specific service has been previously pre-approved with respect to that year, the Audit Committee must approve the permitted service before the independent auditor is engaged to perform it. The Audit Committee pre-approved all of the foregoing services provided to the Company by KPMG in fiscal years ended December 31, 2023 and 2022.


60			Modivcare 2024 Proxy Statement


			TABLE OF CONTENTS

Stockholder Proposals for 2025 Annual Meeting

Pursuant to the applicable rules promulgated under the Exchange Act, Company stockholders are notified that the deadline for providing the Company with timely notice of any stockholder proposal to be submitted and included in the Company’s proxy statement within the Rule 14a-8 process for consideration at the Company’s annual meeting to be held in 2025 (the “2025 Annual Meeting”) will be December 27, 2024.

Pursuant to the Company’s Bylaws, in order for a stockholder to bring a proposal (other than proposals sought to be included in the Company’s proxy statement pursuant to Rule 14a-8 of the Exchange Act) before, or make a nomination of a director at, the 2025 Annual Meeting, such stockholder must deliver a written notice of such proposal and/or nomination to, or it must be mailed and received by, the Company’s Corporate Secretary at the principal executive offices of the Company, located at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237, no earlier than the close of business on February 11, 2025, and not later than the close of business on April 14, 2025. Stockholders are also advised to review the Company’s Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.

As to all such matters which the Company does not have notice on or prior to April 14, 2025, discretionary authority shall be granted to the persons designated in the Company’s proxy related to the 2025 Annual Meeting to vote on such proposal.

In addition, in order to comply with universal proxy rules, a person who intends to solicit proxies in support of director nominees other than the Company’s nominees must provide notice to the Company no later than April 14, 2025 that sets forth the information required by Rule 14a-19 under the Exchange Act, including a statement that such person intends to solicit the holders of shares representing at least 67% of the voting power of the Company’s shares entitled to vote in the election of directors in support of director nominees other than the Company’s nominees.


Modivcare 2024 Proxy Statement			61


TABLE OF CONTENTS

Other Matters

On the date we filed this Proxy Statement with the SEC, the Board did not know of any other matter to be raised at the Annual Meeting. If any other matters properly come before our stockholders at this Annual Meeting, the persons named on the enclosed proxy card intend to vote the shares they represent in accordance with their best judgment.


62			Modivcare 2024 Proxy Statement


			TABLE OF CONTENTS

Additional Information

The Company files reports and other information with the SEC. Copies of these documents may be obtained at the SEC’s public reference room in Washington, D.C. The Company’s SEC filings are also available on the SEC’s web site at www.sec.gov. Stockholders may also request additional copies of the Company’s 2023 Annual Report, except for exhibits to the 2023 Annual Report, without charge, by submitting a written request to the Company’s Corporate Secretary at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237.


Modivcare 2024 Proxy Statement			63


TABLE OF CONTENTS

Householding

In order to reduce printing costs and postage fees, the Company has adopted the process called “householding.” Under this procedure, the Company may deliver a single copy of the Notice, and if applicable, this Proxy Statement and 2023 Annual Report to multiple stockholders who share the same last name and address, unless the Company receives contrary instructions from stockholders at that address. Stockholders who participate in householding will continue to receive separate proxy cards, if applicable.

If you prefer to receive multiple copies of the Company’s Notice or Proxy Statement and the 2023 Annual Report at the same address, you may obtain additional copies by writing to the Company’s Corporate Secretary at 6900 E. Layton Avenue, 12th Floor, Denver, CO 80237 or by calling (720) 703-7016. We will deliver to you promptly any copies so requested. Eligible stockholders of record receiving multiple copies of this Proxy Statement and 2023 Annual Report can request householding by contacting the Company in the same manner.

By Order of the Board of Directors:

L. Heath Sampson

President, Chief Executive Officer and Director

April 26, 2024
Denver, CO


64			Modivcare 2024 Proxy Statement


			TABLE OF CONTENTS

Appendix A

Non-GAAP Financial Measures and Adjustments

In addition to the financial results prepared in accordance with generally accepted accounting principles in the United States (“GAAP”), this Proxy Statement includes EBITDA, Adjusted EBITDA and Compensation Adjusted EBITDA for the Company, which are performance measures that are not recognized under GAAP but that we use to measure the Company’s performance and management’s performance against pre-established performance targets for purposes of determining payouts under our STI. EBITDA is defined as income (loss) before: (1) interest expense, net; (2) provision (benefit) for income taxes; and (3) depreciation and amortization. Adjusted EBITDA is calculated as EBITDA before certain items, including (as applicable): (1) stock-based compensation; (2) equity in net (gain) loss of investee, net of tax; (3) restructuring and related costs, including severance and organizational consolidation costs and professional services fees; (4) certain transaction and integration costs; (5) certain settlement related costs; (6) COVID-19 related costs; and (7) impairment of goodwill. Our non-GAAP performance measures exclude certain expenses and amounts that are not driven by our core operating results and may be one time in nature. Excluding these expenses makes comparisons with prior periods as well as to other companies in our industry more meaningful. We believe such measures allow investors and other interested parties to gain a better understanding of the factors and trends affecting the ongoing operations of our business and how actual payouts under our STI were determined in 2023 and how they fit within the Company’s broader executive compensation program. We consider our core operations to be the ongoing activities to provide services from which we earn revenue, including direct operating costs and indirect costs to support these activities. As a result, our net income or loss in equity investee, net of tax is excluded from these measures, as we and our management do not have the ability to manage the venture in which we have made our investment, allocate resources within the venture, or directly control its operations or performance.

Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. The presentation of non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate our business or the performance of our management.


Modivcare 2024 Proxy Statement			65


Appendix A			TABLE OF CONTENTS

Reconciliation of Adjusted EBITDA of ModivCare


(dollars in thousands)	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023
Net income (loss)	(4,953)	88,836	(6,585)	(31,806)	(204,460)
Provision (benefit) for income taxes	(573)	22,018	8,617	(3,035)	(4,319)
Interest expense, net	850	17,599	49,081	61,961	69,120
Depreciation and amortization	16,816	26,183	56,998	100,415	104,271
Reported EBITDA	12,140	154,636	108,111	127,535	(35,388)
Stock-based compensation (1)	5,414	19,847	13,958	6,068	5,501
Equity in net (gain) loss of investee, net of tax (2)	29,685	(6,411)	38,250	29,964	(287)
Restructuring and related costs (3)	6,691	7,295	21,593	26,998	36,704
Transaction and integration costs (4)	2,693	12,619	25,588	23,971	4,682
Settlement related costs (5)	—	—	—	9,564	10,127
COVID-19 related costs, net of grant income (6)	—	1,204	(2,492)	(2,198)	—
Impairment of goodwill (7)	—	—	—	—	183,100
Total adjustments	44,483	34,554	96,897	94,367	239,827
Adjusted EBITDA	56,623	189,190	205,008	221,902	204,439
Less: Restructuring and related costs in excess of approved budget	N/A	N/A	N/A	(13,898)	N/A
Less: Transaction and integration costs in excess of approved budget	N/A	N/A	N/A	(13,600)	N/A
Less: Settlement related costs in excess of approved budget	N/A	N/A	N/A	(1,435)	N/A
Compensation Adjusted EBITDA 2022 (8)	N/A	N/A	N/A	192,969	N/A
Reported EBITDA	12,140	154,636	108,111	127,535	(35,388)
Add: Impairment of goodwill (7)	N/A	N/A	N/A	N/A	183,100
Add: Settlement related costs related to executive departure	N/A	N/A	N/A	N/A	7,500
Add: Transaction and integration costs for investment in innovation	N/A	N/A	N/A	N/A	9,371
Compensation Adjusted EBITDA 2023 (9)	N/A	N/A	N/A	N/A	164,583

Notes to Reconciliation of Adjusted EBITDA:

1. Stock-based compensation: Stock-based compensation provided to employees and non-employee directors under the Company’s 2006 Long-Term Incentive Plan. This amount includes cash settled equity balances which were previously presented as a separate item

2. Equity in net (gain) loss of investee, net of tax: The Company’s share of net (gain) loss in CCHN Group Holdings, Inc. and its subsidiaries, which operate under the Matrix Medical Network brand (“Matrix”). The Company holds a 43.6% noncontrolling interest in Matrix. The investment in Matrix is accounted for under the equity method of accounting

3. Restructuring and related costs: Restructuring and related costs include professional fees for strategic initiatives, organizational consolidation costs, severance, and other professional fees


66			Modivcare 2024 Proxy Statement


TABLE OF CONTENTS			Appendix A

4. Transaction and integration costs: Transaction and integration costs consist of fees incurred for SOX implementation and business integration efforts. Transaction costs in 2022 include fees incurred in the acquisition of Guardian Medical Monitoring (GMM). Transaction costs in 2021 include fees incurred in the acquisitions of CareFinders and VRI. Transaction costs in 2020 include fees incurred in the acquisitions of Simplura and National MedTrans.

5. Settlement related costs: The Company’s costs associated with certain one-time settlement-related matters

6. COVID-19 related costs: Additional costs required for health and safety precautions due to COVID-19, less grant income due to COVID-19

7. Impairment of goodwill: Impairment of goodwill relates to a non-cash impairment charge that was recorded at the Company’s PCS and RPM segments during 2023

Notes to Reconciliation of Compensation Adjusted EBITDA:

8. Compensation Adjusted EBITDA 2022 : Compensation Adjusted EBITDA in 2022 was utilized by the Compensation Committee to determine the potential STI payout. This amount is calculated by reducing the Company’s publicly disclosed Adjusted EBITDA by the amount by which the operating expenses identified in such reconciliation exceeded the Company’s Board approved 2023 operating budget.

9. Compensation Adjusted EBITDA 2023 : Compensation Adjusted EBITDA in 2023 was utilized by the Compensation Committee to determine the potential STI payout. This amount is calculated by increasing the Company’s publicly disclosed EBITDA by impacts from the impairment of goodwill recorded during the year, settlement related costs from executive departure and transaction and integration costs from an investment in innovation.


Modivcare 2024 Proxy Statement			67


			TABLE OF CONTENTS

Appendix B

Proxy Card


68			Modivcare 2024 Proxy Statement

MODIVCARE INC._PRXY_GT20_P05170_24(#76658) - C1_Page_1.jpg

MODIVCARE INC._PRXY_GT20_P05170_24(#76658) - C1_Page_2.jpg

TABLE OF CONTENTS

Proxy Statement for 2024 Annual Meeting of Stockholders Proxy Statement Summary Voting Procedures Voting Securities of Certain Beneficial Owners and Management Proposal 1 Election of Directors Corporate Governance Executive Compensation Proposal 2 Advisory vote to approve named executive officer compensation Proposal 3 Ratification of appointment of independent registered public accounting firm Audit Committee Report Independent Registered Public Accountants Stockholder Proposals for 2025 Annual Meeting Other Matters Additional Information Householding

MODVQ DEF 14A Report ended April 26, 2024